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In cerebral  ischemia, a central mechanism  leading to neural damage  is energy  failure due to the 
lack of oxygen and glucose  supply but  it has been  shown  that besides glucose, other metabolic 
intermediates such as lactate, pyruvate or acetate can be oxidized for energy production. L‐lactate 
is neuroprotective when administered either after oxygen and glucose deprivation (OGD) or during 
reperfusion  after  transient middle  cerebral  artery  occlusion  (tMCAO).  New  evidence  has  risen 
concerning  the  presence  and  possible  involvement  of  the  Hydroxy‐Carboxylic  Acid  Receptor‐1 
(HCA1)  in nervous system effects of  lactate. Therefore, the objective of the present work was to 




reperfusion  led to  further enhancement of HCA1 receptor expression  in the  ischemic cortex and 
striatum (lesion site). To test the role of the HCA1 receptor we evaluated the effect of a receptor 
agonist, 3,5‐dihydroxybenzoic acid (3‐5 DHBA), in the in vitro OGD. The administration of 3‐5 DHBA 
to  the  organotypic  hippocampal  cultures  after  1h OGD  reduced  cell  death.  Protein  expression 
analysis  revealed  that  the hippocampal cultures  receiving 3‐5 DHBA showed an  increase protein 
expression  of  HCA1  in  comparison  to  the  control  hippocampal  slices. We  also  report  that  D‐
lactate, a reputedly non‐metabolizable substrate but a partial HCA1 receptor agonist also provided 
neuroprotection  in  ischemia models both  in vitro and  in vivo.  It decreased the percentage of cell 
death  in hippocampal  cultures  subjected  to OGD as well as  the  lesion  size and  the neurological 
deficit  in  the mice  receiving  intravenous administration of D‐lactate at  reperfusion, after 45min 
MCAO. Quite unexpectedly, and thanks to collaboration with the group of Prof. Bruno Weber from 
the University Hospital of Zürich, we  show D‐lactate  to be partly extracted and oxidized by  the 




















Dans  l’ischémie  cérébrale,  le manque  d’énergie  relatif  à  un manque  d’apport  d’oxygène  et  de 
glucose est  le mécanisme  central menant à  l’atteinte neural.  Il a été montré que, mis à part  le 
glucose, d’autres intermédiaires métaboliques comme le lactate, le pyruvate ou l’acétate peuvent 
être oxydés pour produire de  l’énergie. Le L‐lactate est neuroprotecteur  lorsqu’il est administré 
soit  après  la privation d’oxygène et de  glucose  (OGD) ou durant  la  reperfusion  après occlusion 
transitoire de l’artère cérébrale moyenne (MCAO). Il a été montré récemment que le récepteur 1 
de  l’acide  hydroxy‐carboxylique  (HCA1)  était  impliqué  dans  certains  effets  du  lactate  dans  le 
système  nerveux.  Ce  travail  a  donc  pour  objectif  de  déterminer  si  le  lactate  exerce  ses  effets 
neuroprotecteurs en tant que substrat énergétique ou à travers les récepteurs HCA1. 
Dans  cette étude, nous avons montré que  l’expression des  récepteurs HCA1 est augmentée 24 
heures  après  la  reperfusion,  dans  le  centre  de  la  lésion,  dans  le modèle    d’accident  vasculaire 
cérébrale chez la souris avec MCAO de 30 minutes. Fait intéressant, l’injection intra‐veineuse de L‐
lactate au moment de  la reperfusion conduit à une augmentation de  l’expression des récepteurs 
HCA1 au niveau du cortex et du striatum  ischémiques (sites de  lésion). Afin de tester  le rôle des 
récepteurs HCA1, nous avons étudié  l’effet d’un de ses agonistes,  l’acide 3,5‐dihydroxybenzoique 
(3‐5  DHBA),  dans  un  modèle  in  vitro  d’OGD.  L’application  de  3‐5  DHBA  sur  des  cultures 
organotypiques  de  l’hippocampe  après  1  heure  d’OGD  a  réduit  la mort  cellulaire.  L’analyse  de 
l’expression des protéines a révélé une augmentation de  l’expression des récepteurs HCA1 dans 






de  la  reperfusion,  après 45 minutes de MCAO. Nous  avons découvert, en  collaboration  avec  le 
groupe  du  Prof.  Bruno  Weber  le  résultat  assez  inattendu  que  le  D‐Lactate  pouvait  être 
partiellement extrait et oxydé par le cerveau de rongeur. Finalement, afin d’explorer un peu plus 
en  détail  la  voie  de  signalisation métabolique,  nous  avons  testé  d’autres monocarboxylates,  le 
pyruvate  et  le  lactate  dans  le  modèle  in  vitro :  le  pyruvate  apporte  une  neuroprotection  en 
diminuant le pourcentage de mort cellulaire alors que l’acétate est inefficace. 















2DG        2‐deoxy‐D‐glucose 
3,5‐DHBA      3,5‐Dihydroxybenzoic acid   
4‐CIN        alpha‐cyano‐4‐hydroxycinnamate 
AHA        American Heart Association 
ALS        Amyotrophic Lateral Sclerosis 
ANLS        Astrocyte‐Neuron Lactate Shuttle 
ANOVA       Analysis of Variance 
AT        Anaerobic Threshold 
ATP        Adenosine Tri‐Phosphate 
cAMP        cyclic Adenosine Monophosphate 
CA1        Cornus Ammonis‐1 
CA3        Cornus Ammonis‐3 
CBF        Cerebral Blood Flow 
CCA        Common Carotid Artery 
CO2        Carbon dioxide 
CoA        acetyl‐coenzyme‐A 
CT        Computer Tomography 
DAPI        4’,6‐Diamidino‐2‐Phenylindole 
DG        Dentate Gyrus 
DMEM        Dulbecco’s Modified Eagle Medium 
DWI        Diffusion‐Weighted Imaging 
EP        Ethyl pyruvate 
ERK        Extracellular signal‐Regulated Kinase 
GFAP        Glial Fibrilar Acidic Protein 
Glu        Glutamate 
GLUT        Glucose Transporter 
Gln        Glutamine 
HBSS        Hank’s Buffered Salt Solution 
HCA1        Hydroxy‐carboxylic Acid Receptor 1 
HEPES        Hydroxyethyl‐Piperazineethane Sulfonic acid 
HLa        Lactic acid 
H2O2        Hydrogen peroxide 
ICA        Internal Carotid Artery 
ICV        Intracerebroventricular 
IgG        Immunoglobulin G 
IP        Intraperitoneal 
IV        Intravenous 
LC        Locus Coeruleus 
LDH        Lactate Dehydrogenase 
MAP2        Microtubule Associated Protein 
MCAO        Middle Cerebral Artery Occlusion 
MCT        Monocarboxylate transporter 
MEM        Minimum Essential Medium 
MRI        Magnetic Resonance Imaging 






NAA        N‐acetylaspartate 
NADH        Nicotinamide adenine dinucleotide 
NeuN        Neuronal Nuclei 
NO         Nitric Oxide 
OGD        Oxygen and Glucose Deprivation 
PBS        Phosphate Buffer Solution 
PET        Positron Emission Tomography 
Pi        inorganic Phosphate 
PI        Propidium Iodide 
PIDs        Peri‐infarct depolarizations 
PO2        Oxygen partial pressure 
rCBF        regional Cerebral Blood Flow  
RIPA        Radioimmunoprecipitation Assay  
rtPA        recombinant tissue Plasminogen Activator 
s.d.        Standard Deviation   
SDS‐PAGE      Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
si‐RNA        small interfering‐ RNA 
SLC16        Solute Carrier 16 
TAT1        T‐type amino‐acid transporter 1 
Tau        Taurine 
TBI        Traumatic Brain Injury 
TBS‐T        Tris‐Buffered Saline‐Tween 
TGI        Transient Global Ischemia 
TOAST        Trial of Org 10172 in Acute Stroke Treatment 


























































































1. New  evidence  of  neuroprotection  by  lactate  after  transient  focal  cerebral 
ischaemia: extended benefit after  intracerebroventricular  injection and efficacy 
of intravenous administration  35




































































Figure 1.Ischemic stroke in the left middle cerebral artery         
Figure 2.  Major pathways involved in ischemic cell damage          
























neuronal   markers         
Figure 12. Confocal visualization of HCA1 receptor expression. HCA1 receptor is not 
expressed in astrocytes                  





Figure 16. HCA1 receptor expression 48h after ischemia         
Figure 17. The HCA1 receptor expression is promoted by ischemia and enhanced by L‐





Figure 21. In vitro neuroprotection by D‐lactate            
Figure 22. In vivo neuroprotection by D‐lactate             
Figure 23. D‐lactate neuroprotection is reflected also in the neurological outcome   






















































































































Ximena  Castillo,  Carole  Berthet,  Maïte  Willaredt,  Pierre  J.  Magistretti,  Lorenz  Hirt;  D‐lactate 
































Mirante  O,  Price  M,  Puentes  W,  Castillo  X,  Benakis  C,  Thevenet  J,  Monard  D,  Hirt  L  (2013) 




















In  1971  the World  Health  Organization  started  the  first  attempt  to  collect  data  on  stroke  in 










of  stroke  subtypes  (Feigin  et  al.,  2009).  According  to  the  American Heart  Association  in  high‐
income countries  the  incidence of stroke has decreased  in  the  last decades  thanks  to  increased 
awareness and control of risk factors as well as early  identification of the disease. The different 
incidence among high, middle and  low  income countries  is possibly due to the  lack of adequate 
technology for proper and fast diagnosis in low and middle income countries. On the other hand, 
the reported increase in stroke incidence in the these countries might reflect the slow shift from a 
traditional  to a Westernized diet and  lifestyle  increasing  the cardiovascular and cerebrovascular 
risk  factors  for  stroke(Reddy, 2004).Population  risk  factors are: hypertension, diabetes mellitus, 
hyperlipidemia,  cigarette  smoking,  cardiac  disease  (atrial  fibrillation,  rheumatic  heart  disease, 
mitral  valve  disease,  infective  endocarditis,  atrial  myxoma  and  mural  thrombi  complicating 
myocardial infarction) and a family history of stroke (Go et al., 2014). 
b) Pathological subtypes 










attacks, atrial  fibrillations and atherosclerosis  risk  factors are more common  in  ischemic stroke. 















































































































































Brain  ischemia  is a diminution of cerebral blood  flow  to below a critical  threshold  that  induces 
brain  damage.  It  can  be  divided  into  global  or  focal  ischemia;  global  cerebral  ischemia  entails 
diminution over the entire brain and happens after different clinical conditions including transient 
circulatory/cardiac arrest, occlusion of cerebral or extracerebral vessels supplying nervous tissue, 


















with neurons  in  the CA1 zone are  the most sensitive  to  ischemic  insult whereas neurons  in  the 
CA3 and DG are able to re‐fuse after 24h of recirculation, making them more resistant to ischemic 
insult (Owens et al., 2014).  
Regarding  the  therapeutic  approach  in  humans,  hypothermia  has  been  shown  to  be  a  safe 




patients  that  received  standard  treatment  with  normothermia.  In  newborns  having  suffered 
neonatal hypoxic‐ischemic encephalopathy, hypothermia has been  shown  to be a  safe  therapy 










surrounded  by  a  region  that  remains  metabolically  active  and  known  as  the  “penumbra”. 
Depending on the rate of residual blood flow and the duration of ischemia the penumbra maybe 
“rescued” when cerebral blood  flow  is  restored early enough otherwise cell death mechanisms 

























Left and middle upper panels  show a  cerebral perfusion  computerized  tomography  (P‐CT) with 




core of the  ischemic  lesion  in the territory of the  left middle cerebral artery. Lower panels show 
angiographic sequences of cerebral CT (left and middle panels) with occlusion of the  left middle 
cerebral artery (arrow). After intravenous administration of rtPA, angiographic sequence of brain 










potential was  completely abolished at a  rCBF of 15 ml  / 100 g per minute  and  that K+  release 
occurred when  systemic  blood  pressure  and  rCBF was  decreased  to  about  8 ml  /  100  g  per 
minute,  demonstrating  that  the  ischemic  threshold  for  K+  release  is  below  that  for  complete 
electrical  failure.  Following  these  results,  two  critical  levels  of  decreased  perfusion  were 
described: a functional threshold, representing the flow threshold for reversible functional failure 
(ischemic  penumbra);  and  a  lower  threshold  below  which  irreversible  membrane  failure  and 
morphological  damage  occur  (ischemic  core)  (Astrup  et  al.,  1977).Following  this  studies  with 
baboons,  in patients with acute stroke  the  thresholds of  ischemic penumbra have been studied 






















sources,  the  lack  of  oxygen  and  glucose  supply  leads  to  a  reduction  in  metabolites  such  as 
ATP(energy depletion)  that will  in  turn promote membrane potential  loss and depolarization of 
neurons and glia (Katsura et al., 1994). Following this depolarization, voltage‐dependent calcium 
channels become activated and excitatory amino acids are released  into the extracellular space. 
As the re‐uptake system of excitatory amino acids  is energy‐dependent, this process  is  impaired 
and  promotes  further  accumulation  of  glutamate  into  the  extracellular  space  which  leads  to 
excitotoxicity: the presence and continuation of peri‐infact depolarizations (PIDs) in the penumbra 
(see  below).  Disturbance  of  the  energy‐dependent  ionic  pumps  leads  to  an  increase  in 
intracellular sodium and extracellular potassium concentrations as well as calcium influx into cells. 
This  increase  in  intracellular  calcium  concentration promotes  activation of proteolytic enzymes 
such as gelsolin that degrade structural constituents of the cell and promotes generation of free‐
radical  species  that  surpass  scavenging mechanisms enhancing  structural damage  (Furukawa et 
al., 1997; Chen et al., 1997). Anaerobic metabolism causes increases in brain tissue osmolality and 
























Importantly,  if  perfusion  of  the  ischemic  tissue  is  restored  within  minutes,  cytotoxic  edema 
(hyperosmotic)  might  be  reversible.  Nevertheless  if  the  ischemic  episode  persists  different 
proteases  are  induced  which  leads  to  disruption  of  tight  junctions,  degradation  of  the  basal 
lamina, and breakdown of the blood‐brain barrier (Battey et al., 2014; Yang and Rosenberg, 2011). 
The opening of the blood‐brain barrier allows influx of neutrophils and formation of cytokines and 
chemokines; activated microglia and macrophages are  found especially  in peripheral  regions of 
the  ischemic  territory  since  they play a  role  in  the clearance of damaged  tissue and have been 
found in patients with ischemic stroke in the territory of the middle cerebral artery(Gerhard et al., 
2005; Cagnin et al., 2007; Benakis et al., 2010).  In  the penumbra, where some energy supply  is 
preserved, cells can  re‐polarize and depolarize again  in  response  to  increased glutamate  levels. 
Repetitive  depolarizations  or  PIDs  can  last  for  hours  after  ischemia,  promoting  a  misrelation 
between the increased metabolic workload and the low oxygen supply leading to further transient 
episodes  of  hypoxia.  Therefore,  the  higher  the  rate  of  PIDs  the  faster  the  tissue  evolves  into 
terminal depolarizations (Back et al., 1996) Further cell death in the ischemic penumbra is mainly 
driven  by  apoptosis  promoted  in  turn  by  the  release  of  cytochrome  c  from  the  outer 
mitochondrial membrane (Doyle et al., 2008). 
 










collateral blood  flow  can  counteract  the most detrimental effects of  the  stroke,  the degree of 






To study the molecular mechanisms  involved  in the neurological damage after cerebral  ischemia 
with the goal of finding therapeutic targets suitable for translation to the clinical practice, many 
different models of in vivo and in vitro cerebral ischemia have been developed in rodents. To try 
to  replicate  the diverse manifestations  in  vivo,  causes  and  anatomic  sites of  stroke  in humans 









point  is  to achieve neuroprotection and  improved outcome  in an experimental setting, defining 
appropriate doses, modes and time of administration that may then be tested in clinical trials for 
an  eventual  translation  “from  the  bench  to  bed‐side”.  A  brief  introduction  to most  common 


















‐ Levine preparation of hypoxia‐ischemia: Originally described as unilateral CCA  ligation  in 
rats followed by a gradual exposure to an anoxic environment for 45 minutes, 24h after 
occlusion. Even  though  this model was originally described  for use  in adult animals  it  is 
now  used  more  commonly  to  assess  the  effects  of  neonatal  hypoxia‐ischemia  in  an 




‐ Photochemically  induced  focal  cerebral  thrombosis:  Starting  from  the  principle  that 




at 560nm  to generate  singlet oxygen, which peroxidizes  lipid molecules at  the vascular 
endothelium and promotes microvascular platelet aggregation (Watson et al., 1985). 
‐ Suture Middle  Cerebral  Artery Occlusion  (MCAO):  This method  can  be  used  either  for 
permanent or transient ischemia generation and is widely accepted as a reliable model for 
studying focal cerebral  ischemia. The MCAO method used for the experiments described 
in  this  thesis  is a  variation of  the model proposed by  Longa et al.  (Longa et al., 1989), 
consisting of  a  transient  regional  cerebral  ischemia  elicited by occlusion of  the CCA by 
advancing an  intraluminal  suture  from  the CCA  to  the  internal carotid artery  (ICA) until 




MCA  artery  arises  from  the  internal  carotid  artery  and  along  its  path  it  branches  and 








An  advantage  of  this model  is  that middle  cerebral  artery  occlusion  is  responsible  for 
many of the  ischemic stroke episodes  in humans making the model particularly relevant 





‐ In  vitro  transient  oxygen  and  glucose  deprivation  of  organotypic  hippocampal  slice 
cultures is a widely used model of ischemia since it has been shown to promote necrotic 
and apoptotic cell death phenotypes depending on the magnitude of the environmental 
ischemic  insult  (Gwag et al., 1995; Kalda et al., 1998). As  the environment can be more 
easily  controlled,  this  technique  is  useful  not  only  to  elucidate molecular mechanisms 
behind  neuronal  cell  death  /  protection,  but  also  to  assess  pharmacological  influences 
over  the  same  detrimental  /  beneficial  mechanisms.  The  limitation  of  course  is  that 
interactions between different brain structures are not considered in this approach, which 





Figure  3.  Diagram  of  cerebrovascular 
anatomy  of  a  rat.    The  middle  cerebral 
artery  occlusion  technique  consists  of  the 
insertion of a filament through the common 
carotid  artery  into  the  internal  carotid until 
reaching  the  beginning  of  the  middle 
cerebral artery where  the  filament  is  left  in 


















possible.  Currently,  only  the  intravenous  administration  of  recombinant  tissue  plasminogen 
activator  (rtPA),  a  thrombolytic  agent,  is  approved  to  be  administered  up  to  4.5h  after  the 
beginning of symptoms  in selected patients. The earlier the drug can be supplied the better the 
outcome expected. Nevertheless, treatment with rtPA is associated with symptomatic intracranial 
hemorrhage  that  is  complicated  to manage  and  can  be  fatal.  Therefore,  a  careful  selection  of 
patients and scrupulous monitoring and secondary care is mandatory (Adams et al., 2003). 
It  was  recently  described  that  intraarterial  thrombolysis  of  the  blood  clot  causing  ischemia 
administered within 6 hours after stroke onset in patients with a proximal intracranial occlusion of 
the  anterior  circulation  is  safe  and  beneficial.  Mechanical  clot  removal  increased  the  rate  of 
functional  independence of the patients that received the  intraarterial treatment,  in comparison 
with patients that did not (Berkhemeret al., 2015).  It should be noted that this treatment  is not 























Despite  the  tremendous  amount  of  efforts  worldwide  and  the  incredible  progress  in  the 




50 neuroprotective agents were studied  in about 114  trials and only  few  trials showed positive 
results: the Neurological Institute of Neurological disorders and Stroke (NINDS) rtPA trial, Prolyse 
in Acute Cerebral Thromboembolism (PROACT II), a low‐molecular‐weight heparin trial (Kidwell et 
al., 2001). Another analysis  that  included not only  the drugs  tested  in clinical  trials but also  the 
experimental ischemia results was released in 2006. Systematic research of controlled in vivo and 
in vitro experiments using functional or histological end points were selected for analysis: a total 
of  8516  experimental  results  were  extracted  from  approximately  3500  papers.  Final  analysis 
included7,554 experimental results from models of focal ischemia (3,867 results), global ischemia 
(1,546 results), and in vitro models (1,341 results) (O’Collins et al., 2006).And even though out of 
the  1026  candidate  stroke drugs  identified, neuroprotective  efficacy was  shown  in  62% of  the 
focal  ischemia experimental results,  in 70% of global  ischemia models and  in 74% of the  in vitro 
models, only few studies show efficacy when administered to humans (studies mentioned above).  
Importantly,  the  consensus  is  that  neuroprotection  could  be  achieved  but  by  studying  the 
molecular mechanisms triggered not only in neurons after stroke but also in other cell types that 
likely participate in neuronal survival or play a role in repair mechanisms. For example, the supply 














size,  impressively  the brain uses about 20% of  the  total oxygen and  caloric  intake  (Raichle and 
Gusnard, 2002). Brain energy metabolism is a compartmentalized process involving different cells 
such  as neurons,  astrocytes  and oligodendrocytes, with  interactions between  the different  cell 
types.  
 
Glucose  is  known  as  the  brain  energy  substrate  par  excellence  and  generation  of  metabolic 
energy from glucose starts with glycolysis, which is a sequence of reactions that converts glucose 
into pyruvate with concomitant production of ATP (substrate phosphorylation). In normal resting 
brain  cells,  pyruvate  then  enters  mitochondria,  where  it  is  converted  to  acetyl‐CoA  and  is 
completely oxidized to carbon dioxide through the citric acid (Krebs) cycle. Most of the glucose‐
derived ATP  is generated  in mitochondria as  the  result of  the  transfer of electrons  from FADH2 
and NADH, formed in the citric acid cycle, to oxygen (oxidative phosphorylation). Before ATP and 
pyruvate are generated in the cytosol, a hydrogen ion and two electrons must be transferred from 





2.5  mol  by  means  of  the  malate‐aspartate  shuttle)  by  oxidative  phosphorylation  (Brand  and 
Chappell, 1974; Minn and Gayet, 1977; Dennis and Clark, 1978). Reduction of pyruvate to lactate 
is another  important way  to  regenerate NAD+, because  it  is extremely  rapid and coupled  to an 
equimolar re‐oxidation of NADH generated by glyceraldehyde 3‐phosphate to NAD+ generated by 
lactate  dehydrogenase(Mintun  et  al.,  2004).  It  has  been  reported  that  during  physiological 




This  increase  in  lactate  levels  is of special  interest since  it was clear as early as 1953 that other 
metabolic  intermediates  such  as  monocarboxylates  including  lactate,  pyruvate,  acetate  and 











of  sustaining  neuronal  activity  for  periods  of  up  to  hours  in  the  almost  complete  absence  of 







for  the  acute phase of  ischemic  stroke  is  short  and  in  an  important number of patients  is not 
possible  to  determine  the  onset  of  the  ischemia,  therefore  leaving  them  without  treatment 




attacks  from  minor  strokes  or  moderate  strokes  based  on  metabolite  concentration  in  the 
ipsilateral striatum, where the  lesion core  is  located. Specifically, a scatter plot of a combination 
score  of  N‐acetylaspartate  (NAA),  glutamate  (Glu)  and  taurine  (Tau)  against  glutamine  (Gln) 




Figure  4.  Scatter  plot  showing  a  combination  of  4 
metabolites.  Combination  of  the  4  metabolites  at  3 
hours after reperfusion allows a good separation among 
the 4 groups. Glutamine (Gln) is increased in all ischemic 











Because  in  the  set  of  experiments  described  before  only  mice  with  good  reperfusion  after 
removal of the silicon filament were considered for the biochemical analysis and considering that 
permanent  ischemia  is  a  condition  observed  in  stroke  patients  in  need  of  revascularization, 
further investigation was performed with the same non‐invasive approach to permanent ischemia 
(MCAO  without  reperfusion)  in  mice  (Berthet  et  al.,  2014).  They  demonstrated  that  the 




the  ischemic  insult, an extremely relevant finding  if this can be extended to stroke patients and 















Lactate was  considered  for  a  long  time  as  a  dead  end metabolite  of  glycolysis  resulting  from 
muscle hypoxia and a major cause of muscle fatigue. In the early 80’s muscular lactate production 
was  used  to  study  the  anaerobic  threshold  (AT)  at which metabolic  acidosis  (during  exercise) 






Ingemann‐Hansen et al., 1981). The AT  theory  is  that elevated  lactic acid  (HLa) production and 
concentration  during  muscular  contraction  or  exercise  are  the  result  of  O2‐limited  oxidative 
phosphorylation.  Nevertheless,  over  the  last  30  years,  there  has  been  evidence  showing  that 
anoxia and hypoxia are not necessarily  the  cause of  increased HLa production  (Banqsbo et al., 
1994; Richardson et al., 1998; Gladden, 2000). Therefore, we can consider that O2  is one of the 
several  factors  that  promote  an  increase  in  muscle  and  blood  HLa  at  submaximal  exercise 
intensity. Because lactic acid is almost completely dissociated into lactate anions and protons (H+) 
at physiological pH and the reported increase in lactate and H+ levels in muscle and blood during 





moderate or  intense  exercise has been widely  studied.  It  is now  known  that  at  rest,  lactate  is 
released  into  the  blood  stream.  During  exercise,  muscles  produce  lactate  rapidly  while  its 
clearance  is  slowed.  This promotes  an  intramuscular  accumulation of  lactate  and  an  increased 
release of lactate into the blood. The lactate that remains in the muscle can then be taken up by 
neighboring oxidative muscles and used as fuel, in a cell to cell lactate shuttle manner (Stanley et 
al.,  1986).  Most  of  the  lactate  taken  up  by  muscles  undergoes  oxidation,  mainly  by  skeletal 
muscles contracting in a submaximal steady state. The lactate released into the blood stream will 









that  secures a  sustained  flux  through  the pentose phosphate pathway,  the problem being  that 







a polymer of glucose  that  in  the brain  is worth 10‐15 minute of  the  resting metabolic  rate and 
even  though  astrocytes  do  not  make  glucose  from  glycogen,  they  can  produce  lactate. 





The  astrocyte‐neuron  lactate  shuttle  (ANLS)  proposed  in  1994  by  Pellerin  and  Magistretti, 
postulates  that activated neurons use  lactate provided by astrocytes as energetic  fuel  (Pellerin 
and  Magistretti,  1994).  According  to  this  hypothesis  at  glutamatergic  synapses  the  effect  of 
glutamate is terminated by an uptake system located in the astrocytes that surround the synaptic 
complex. The glutamate uptake  is coupled with Na+ uptake and  the  increase  in  intracellular Na+ 
concentration  in  the  astrocyte  stimulates  the  Na/K  ATPase  pump, which  in  turn will  activate 
astrocyte  metabolism  to  supply  ATP  to  restore  the  Na+/K+  balance  and  to  supply  energy  for 
glutamine  synthesis  from  the  glutamate  that  has  been  taken  up.  Therefore  glucose will  enter 
astrocytes  from  the blood stream and  the  lactate produced as  the  result of metabolism will be 







the  neurovascular  unit  showing 




together  with  Na+.  This  will  activate 
astrocyte  metabolism  leading  to  the 
production  of  lactate  as  a  result  of 
glucose  glycolysis.  The  lactate 
produced  will  be  exported  to  the 









A number of  studies have given evidence  supporting  the ANLS hypothesis.  For example,  it has 
been  reported  that  lactate and pyruvate serve as  fuel supporting axon  function  in  the  rat optic 
nerve  (Brown et al., 2001) and  that  lactate  could  substitute  (or be preferred  to)  for glucose  in 
cultured cortical neurons (Pellerin et al., 1998; Bouzier‐Sore et al., 2003). The ANLS has also been 
proposed  in  other  cell‐neuron  energetic  support  interactions  such  as  those  between  Schwann 
cells  and  peripheral  neurons  (Véga  et  al.,  1998), Müller  glial  cells  and  photoreceptors  (Poitry‐
Yamate et al., 1995).  In vivo  in anesthetized rats using a paradigm  involving  radiotracer kinetics 
and brain activation it was shown that lactate, as the primary energy source was able to maintain 
neuronal  activity  during  severe  insulin‐induced  hypoglycemia  (Wyss  et  al.,  2011).  Supporting 




for  glycogen‐derived  lactate  has  been  suggested  from  the  observation  that  pharmacological 
inhibition  of  glycogen  phosphorylase  in  rat  hippocampus  impaired  the  formation  of  long‐term 
memory, an effect that could be rescued by exogenous lactate (Suzuki et al., 2011; Newman et al., 
2011).  Genetic  knockdown  of  the  lactate  transporters  of  astrocytes  (MCT4),  oligodendrocytes 
(MCT1), and neurons (MCT2) induced amnesia. Interestingly, exogenous lactate rescued memory 





subject  to  different  challenges  and  criticisms  (Fillenz,  2005).  Assuming  energy  supply  would 
necessarily need to match energy consumption to sustain neuronal activity (propagation of action 
potentials), different  groups have used a battery of  techniques  to measure  the  time  course of 
changes  in  lactate  resulting  from  neuronal  activation,  ranging  from  nicotinamide  adenine 
dinucleotide  (NADH)  flurorescence  in  rat  hippocampus  to magnetic  resonance  spectroscopy  in 
humans. They have reported that brief stimuli (either tail pinch in the rat, electrical stimulation of 
Schaffer  collaterals  or  a  1‐s  visual  stimulus  in  healthy  volunteers)  promote  an  initial  oxidative 







concentration with  high  temporal  resolution  in  the  hippocampus  of  rat  brain,  Hu  and Wilson 
showed  an  increase  in  extracellular  lactate  concentrations  in  response  to  acute  neuronal 
activation that will supply local energy to keep homeostasis and to counteract transport limitation 
of glucose from the blood stream through the blood brain barrier. By comparing the reduction of 
extracellular  glucose  (21%)  versus  the  reduction  in  the  extracellular  pool  of  lactate  (7%)  after 
electrical stimulation of the Schaffer collaterals they conclude that glucose  is the main substrate 









the  uptake  of  synaptically  released  glutamate  a  characteristic  that  could  in  turn  explain  the 
pattern of lactate release described in the studies mentioned in humans (abrupt increase seconds 
after  acute  neuronal  activation  and  maintenance  of  high  levels  of  lactate  afterwards) 
(Bernardinelly et al., 2004; Kasischke et al., 2004; Mangia et al., 2003).  
This  information allows us to conclude that  local  lactate production  is  indeed taking place  in the 
brain  under  specific  circumstances  and  lactate  is  acting  as  a  key  player  in  brain  energy 





lactate  and  pyruvate  could  maintain  electrical  activity  in  human  brain  slices,  Schurr  et  al., 
demonstrated the ability of brain tissue to maintain normal neuronal activity  in rat hippocampal 
slices using  lactate as the sole energy substrate (Schurr et al., 1988). This early observation was 







recovery  of  neuronal  function  upon  re‐oxygenation,  thus  demonstrating  that  lactate  could  be 
used as an effective energy substrate (Schurr et al., 1997b; Cater et al., 2003). In vivo confirmation 
of  this neuroprotective effect was obtained with a model of  transient global  cerebral  ischemia 
(TGI)  in  rats where  the monocarboxylate  transporter  inhibitor alpha‐cyano‐4‐hydroxycinnamate 
(4‐CIN) was administered by intraperitoneal injection (IP). After 5 min of TGI, rats pretreated with 




exposing  hippocampal  slices  to  two  different  concentrations  of  glutamate  with  or  without 
previous treatment with 4‐CIN. They showed that hippocampal slices treated with glucose could 
tolerate 15 min  activation  induced by  glutamate  administration except  if  the monocarboxylate 
transport was blocked. If cells are unable to transport lactate, administration of glutamate yields 
permanent  loss of neuronal function.  Interestingly, when glycolysis was  inhibited by the glucose 
analog  2‐deoxy‐D‐glucose  (2DG)  administration  of  glutamate  reduced  the  number  of  slices 
capable  of  normal  neuronal  function  after  the  stimulus,  but  when  lactate  was  administered 
concomitantly with 2DG the majority of the hippocampal slices showed normal function after the 
glutamate challenge (Schurr et al., 1999). By using an in vivo excitotoxicity model Ros et al., tested 
lactate  ability  to  protect  against  glutamate  neurotoxicity  by  infusing  medium  containing 
glutamate with or without lactate into the cortex of non‐anesthetized rats. When glutamate was 
infused with  lactate  a  reduction  in  the  lesion  size was  observed  in  comparison  to  the  lesion 
elicited by perfusion of glutamate alone (Ros et al., 2001). 
Taking this information into account, in this lab Dr. Berthet performed a series of experiments in 
vitro  to  test  the  effect  of  lactate  administration  after  reoxygenation,  demonstrating  that 
administration of L‐lactate to rat organotypic hipoccampal slices directly after oxygen and glucose 
deprivation (OGD) was protective  in that  it resulted  in decreased cell death  in the CA1 region of 
the hippocampus  at 48h.Berthetcould  also  show  that  L‐lactate  administration  in  vivo either by 
intracerebroventricular (ICV) or intravenous (IV)injection was protective when administered after 
either 15, 30 or 60 min middle cerebral artery occlusion (MCAO) in young adult mice, decreasing 











exerts  protection  to  organotypic 
hippocampal slice cultures subjected to 30 
minutes oxygen and glucose deprivation by 
decreasing  the  percent  of  cell  death 
(Berthet  et  al.,  2009). 
 
 




to an  ischemic episode providing  important data  regarding endogenous effects of  lactate  after 
increased  energy  demands  (Sala  et  al.,  2013).To  further  elucidate  if  exogenous  lactate 
administration  improves  cerebral  energy  metabolism,  Bouzat  et  al.,  provided  an  intravenous 
infusion of hypertonic sodium lactate to patients with severe TBI and monitored the PO2 in brain 
tissue using cerebral microdialys  is as well as  intracranial pressure. They reported an  increase  in 
the amount of extracellular pyruvate and glucose as well as a decrease in extracellular glutamate 
levels.  This  would  mean  that  supplemental  lactate  from  the  systemic  circulation  may  be 
converted by the brain into pyruvate to be utilized aerobically, helping the injured human brain by 
not only providing an energetic substrate but also by sparing cerebral glucose (Bouzat et a., 2014). 
This  study  demonstrates  that  lactate  is  used  as  an  alternative  energy  source, while  glucose  is 




Glycolysis described by Krebs around 1937  is a  sequence of  reactions  that convert glucose  into 
pyruvate  with  a  small  production  of  ATP.  Further  oxidation  of  pyruvate  in  the  mitochondria 
produces most  of  the  energy  contained  in  glucose.  This  dogma  has  been  challenged  in more 






metabolic  pathway,  beginning  with  glucose  and  ending  with  the  production  of  carbon 
dioxide(CO2), water  involving  the mitochondrial electron  transport chain,  thanks  to  the enzyme 
lactate dehydrogenase  (LDH)  that  converts  lactate  to pyruvate  (Schurr, 2014). Therefore, other 
monocarboxylates  located downstream of  lactate oxidation  such as pyruvate and acetate have 
been studied as alternative energy substrates in conditions of increased energy demand. Indeed, 
many  in  vitro  studies  have  shown  neuroprotection  using  pyruvate  acting  as  a  glutamate  and 
hydrogen  peroxide  (H2O2)  scavenger.  For  example,  it  has  been  described  that  pyruvate 
administration  improves  survival  of  cultured  mouse  striatal  neurons  from  mouse  embryos 
exposed  to  H2O2  (Desagher  et  al.,  1997;  Boyko  et  al.,  2011),  and  decreases  neurotoxicity  in 
cultured mouse cortical neurons  induced by either chronic or acute exposure to zinc (Sheline et 
al.,  2000).  It  has  also  been  shown  to  protect  rat  astrocytes  subjected  to  oxygen  and  glucose 
deprivation (Sharma et al., 2003).  Its beneficial effect has also been shown  in vivo  in a model of 




24h  or  14  days  after  the  ischemic  insult  (Yi  et  al.,  2007).  It was  necessary however  to use  an 
incredible number of animals to prove the beneficial effect of pyruvate administration (402 rats), 
perhaps due to pyruvate instability in aqueous solutions. To overcome this problem some groups 
have used  the ethyl ester of pyruvic acid,  i.e. ethyl pyruvate  (EP), showing a beneficial effect  in 
rats  that  received  an  IP  injection  of  EP  following  transient  focal  ischemia.  This  rats  developed 
smaller  lesions  and  showed  less neurological deficit when  EP was  administered  as  late  as  24h 
after  tMCAO  (Yu  et  al.,  2005;  Kim  et  al.,  2005).  Nevertheless,  the  question  regarding  if  the 
modification  in  the  compound  might  be  the  responsible  for  the  protection  observed  by  EP 
administration and not by the pyruvate itself has been raised. 




uptake  of  acetate  into  astrocytes  by  the monocarboxylate  transporter  (MCT)  1,  expressed  in 
astrocytes and absent  in the synaptosomes  (Waniewski and Martin, 1998), rather than a higher 







has arose  in recent years as a molecule of  interest  in the brain energy metabolism field(Wyss et 
al., 2009; Hosoi et al., 2009).In vivo a marked reduction in acetate uptake has been demonstrated 
after  short‐term  MCAO,  mainly  in  the  ischemic  core  (striatum)  (Hosoi  et  al.,  2007)  and 
interestingly it has been shown the important contribution of glial cells to the survival of neuronal 
cells after  ischemic  injury using  infusion of  fluorocitrate, a  selective glial  toxin directly  into  the 





by diffusion but use  a  specific  transport  system  to  cross  the blood‐brain barrier  into  each  cell 
type, or to transfer from one cell type to the other when monocarboxylates are produced locally. 
Monocarboxylates can be transported to and from different cell types with different degrees of 




a monocarboxylate  transporter  (Friesema  et  al.,  2003)  and  only  the  first  four  (MCT1‐4) were 
shown  to  cotransport  monocarboxylates  and  protons  (Halestrap  and  Price,  1999).  Studies 
performed mainly on MCT1 using xenopus laevis oocyte mutagenesis on and molecular modeling, 
rotating  the C‐termini domain have demonstrated  that MCTs have 12  transmembrane domains 
with  the N‐ and C‐  termini  located  intracellularly and  the  transport action  itself  taking place as 
follows: binding of  the proton  followed by binding of  the  anion, domain  rearrangement which 
allows the passage from the extracellular to the  intracellular space of the anion and the proton, 









acid  protonates  Lys38  (K)  causing  the  channel  to  open.  Lactate  then  moves  into  the  open 
extracellular side of the pore and forms an ion pair with Lys38. In the next step the proton on Lys38 
is transferred to aspartate 302 (D‐) neutralizing the aspartate side chain (DH). This is followed by 
migration of  lactate through the pore where  it forms an  ion pair with R306 (R+). The size of the 
adjacent side chain of residue 360 (F) governs the ability of this site to bind the α‐hydroxy acid. 
Once Lys38is deprotonated, and  lactate  is occupying the specificity  filter, the  transporter relaxes 




gradients as  the driving  force allowing  the migration of  the monocarboxylates  from  the  site of 
production to the site of consumption. As such, MCTs have an important role in metabolism, since 
an  important  part  of metabolic  communication  between  different  cell  types  depends  on  their 
proper  function.  Of  the  four  monocarboxylate  transporters  known  to  cotransport 
monocarboxylates and protons, MCT1, MCT2 and MCT4 are the main MCTs in the central nervous 
system and their distribution can be distinguished as follows: 
 MCT1 was  found  to be present  in almost all  tissues  including muscle,  kidney,  liver and 

















(liver  or  kidney)  or  cells  (neurons)  exhibiting  important  monocarboxylate  uptake  and  /  or 












human  chromosome  12: HCA1, HCA2  and HCA3  and whereas HCA1  is  activated by  lactic  acid, 
HCA2 and HCA3 (formerly known as GPR109A and GPR109B) are activated by the ketone body 3‐
hydroxy  butyric  acid  and  the  β‐oxidation  intermediate  3‐hydroxy‐octanoic  acid,  respectively 
(Offermans, 2014). Of  the  three HCA receptors, HCA1 appears  to be  the phylogenetically oldest 
receptor  and  is  found  in most mammals  as well  as  in  fish  (Kuei  et  al.,  2011).Functional HCA2 
ketone body receptors have been described only in mammals, whereas the gene encoding HCA3 
is  present  only  in  the  genome  of  higher  primates  (Zellner  et  al.,  2005).  In  humans,  the  three 
receptors have been involved in the inhibition of lipolysis under different physiological conditions. 











Figure  9.Distribution  of  different  HCA  receptors  expression  in  the  human  body  including  the 
cellular functions regulated via hydroxyl carboxylic acid receptors (Offermanns, 2014). 
 
Originally  described  as  being  expressed  in  a  “highly  restricted” manner  in  adipose  tissues  and 
upregulated during adipocyte differentiation  (Wise et al., 2003; Ge et al., 2008)  for many years 
the  focus of HCA1  receptor  research was on adipose  tissue and  its possible  involvement  in  the 
insulin‐induced inhibition of lipolysis. In fact, it was described that activation of the HCA1 receptor 
by  lactate was able to  inhibit cAMP synthesis  inhibiting  lipolysis (Liu et al., 2009) and this result 
was  confirmed  and  replicated  using  transgenic mice  lacking  the HCA1  receptor  (Ahmed  et  al., 
2010). Since it was reported that mice lacking HCA1 showed reduced weight gain when they were 
































Figure 10. HCA1  is present  in neurons  (A and C) and  in astrocytes  (B and D).Immunolabeling of 
coronal paraffin‐embedded sections demonstrates  the presence of HCA1  in cellular elements  in 
hippocampus CA1 (A and B) and cerebellum (C and D). In the hippocampus, HCA1 is concentrated 
in  perikarya  and  proximal  parts  of  dendrites  of  pyramidal  cells.  In  the  cerebellum,  HCA1  is 
concentrated  in Purkinje  cell perikarya or  synaptic glomeruli,  in  the granule  cell  layer. Sections 
were counterstained with DAPI to show cell nuclei (Lauritzen et al., 2014) 
 




disorders such as cerebral malaria  (Mariga et al., 2014), and a  rather controversial  recent work 











an  energetic  substrate  by  conversion  to  pyruvate  and  further  oxidation  in  the mitochondria. 
Therefore, the recent finding of HCA1 as lactate receptor and its expression in the central nervous 













be  analyzed with  confocal microscopy  by  using  an  immunohistochemistry  approach  in 
























‐ Glucose, pyruvate and acetate administration, metabolites known  to be oxidized  in  the 
mammalian brain, as well as D‐lactate, will be analyzed using the in vitro ischemic model 
to  evaluate  the  participation  of  the  metabolic  pathway  in  the  protection  exerted  by 
lactate  administration.  The  different  substrates  will  be  administered  after  OGD  to 




































mM  for  1  h  at  37  °C  in  a  humid  normoxic  atmosphere.  For  recovery,  cultures  where  then 
transferred  into  fresh  culture medium  at 33  °C  for 48 h. Cultures were  randomly  treated with 
either D‐lactate, pyruvate, acetate  (Sigma‐Aldrich, St. Louis, MO, USA, diluted  in 1 x phosphate‐
buffered  saline, PBS, pH 7), 3,5‐dihydroxybenzoic acid  (3,5‐DHBA, Sigma‐Aldrich, St.  Louis, MO, 









Cell death was determined  in  the CA1  region using  the  fluorescent viability  indicator propidium 
iodide  (PI).  PI was  applied  in  each  dish  (50  µg/mL)  1  h  before measurement.  PI  fluorescence 
emission  (excitation wavelength 536nm,  emission wavelength  617nm) was measured 48 hours 
after hypoxia using an epifluorescence microscope with a 5x lens coupled to a camera (Leica). PI 
images were acquired with standardized camera settings and signal intensity was measured with 
ImageJ  software  (ImageJ 1.36b, National  Institute of Health). After  subtracting  the background 






maintained  at  37.0  ±  0.5°C  throughout  surgery  (FHC  Inc.,  Bowdoinham,  ME,  USA).  Regional 
cerebral blood flow (rCBF) was measured and continuously recorded throughout the operation in 
all animals by  laser‐Doppler  flowmetry  (Perimed) with a  flexible probe  fixed on the skull  (1 mm 
posterior and 6 mm  lateral  from bregma). Transient  focal cerebral  ischemia  (30 min or 45 min) 
was induced by occlusion of the left MCA with an intra‐arterial suture (Longa et al., 1989). Briefly, 
the  left  common  carotid  artery  and  the  left  external  carotid  artery were  exposed  and  ligated 
following a ventral midline neck incision. Ischemia was induced by inserting a silicon‐coated nylon 
monofilament  (0.17  mm  diameter)  through  the  left  common  carotid  artery  into  the  internal 
carotid  artery  until mild  resistance was  felt  and  a  drop  to  less  than  20 %  of  initial  rCBF was 
registered. rCBF was monitored and maintained below 20 % of the baseline level during ischemia. 
Reperfusion was considered successful  if  the  rCBF  rose above 50 % of baseline. Five microliters 




At  the  beginning  of  the  surgery,  mice  were  administered  0.025  mg/kg  of  buprenorphine 








neuroscore  graded  for  severity  after  surgery  (0:  no  observable  neurologic  deficit;  1:  failure  to 
extend  the  right  forepaw; 2: circling  to  the contralateral side, and 3:  loss of walking or  righting 
reflex) as previously described elsewhere (Longa et al., 1989) and motor performance assessed on 
the  Rotarod  treadmill  (UgoBasile, Milan,  Italy).  In  this  test, mice were  placed  on  the  rotating 
cylinder, set  to accelerate uniformly  from 4  to 40  r.p.m., and  their  latency  to  fall was  recorded 
before 600 seconds. The animals were trained on 2 different days before surgery, with two trials 
in  each  training  session.  The  test  was  then  performed  24  and  48  h  after  MCAO,  with  two 
consecutive  trials  for  each  animal.  The  better  of  the  two  trials  was  selected.  Points  were 






coronal  cryostat  sections were  stained with  cresyl  violet  for  histologic  determination  of  lesion 
size. Digitalized  images of the Nissl‐stained tissue were acquired under a  light stereomicroscope 
(Leica MZ16FA)  and  the  lesion  area was measured  using  ImageJ  software.  Infarct  volume was 

















blue).  Samples  were  separated  on  a  10  %  acrylamide  gel  with  a  4  %  stacking  gel  using  an 
Electrophoresis  Unit  (Bio‐Rad,  Cressier,  Switzerland).  Proteins  were  then  electroblotted  onto 
nitrocellulose  membranes  (0.45  µm;  #162‐0115,  Bio‐Rad,  Cressier,  Switzerland)  using  the 
Electrophoresis Unit. Nonspecific binding sites were blocked for 1 hour at room temperature with 
a  solution  of  Tris‐Buffered‐Saline  (TBS‐T;  50 mM  Tris‐HCl  pH  7.5,  150mM NaCl)  supplemented 
with  0.1 %  Tween‐20  and  containing  10 %  (wt/vol)  skimmed milk.  Blots were  then  incubated 
overnight at 4°C with  specific primary antibodies  in TBS‐T 0.1 %  containing 1 %  skimmed milk: 
rabbit anti‐mouse GPR81‐S296 (HCA1) (1:500 dilution; #SAB1300790, Sigma, Buchs, Switzerland). 
Blots  were  washed  three  times  in  TBS‐T  0.1%  and  subsequently  incubated  2  h  at  room 
temperature  with  horseradish  peroxidase‐conjugated  donkey  anti‐rabbit  IgG  (#NA9340V, 
1:10.000 dilution; GE Healthcare, Glattbrugg, Switzerland). After being washed three times in TBS‐
T  0.1%,  blots  were  processed  using  Immun‐StarTMWesternCTM  Chemiluminescent  Kit  (#170‐
5070,  Bio‐Rad,  Cressier,  Switzerland).  Chemiluminescence  detection  was  performed  with  the 
ChemiDoc™ XRS System  (#170‐8070, Bio‐Rad, Cressier, Switzerland). Total protein content assay 
was  performed with  the  Pierce  Reversible  Protein  Stain  kit  (#24580,  Thermo  Fisher  Scientific, 





Mice  were  injected  intraperitoneally  with  a  lethal  dose  of  pentobarbital  (10mL/kg,  Sigma, 
Switzerland)  and  then  perfused  with  150mL  of  4%  paraformaldehyde  (Sigma‐Aldrich,  USA) 
dissolved  in 1 x PBS at pH 7.4. Brains were dissected, postfixed overnight at 4°C, cryoprotected 






antibodies: monoclonal mouse  anti‐neuronal  nuclear  antigen  (NeuN)  antibody  (1:500  dilution, 






Sigma). After washing  three  times with 1  x PBS, brain  sections were  incubated  for 2h at  room 
temperature with  the  following  fluorescent  secondary antibodies: donkey anti‐rabbit Alexa‐594 
(1:250, Invitrogen), donkey anti‐mouse Alexa‐488 (1:250, Invitrogen) for 2h at room temperature. 








analysis of  in vitro experiments and  the Mann‐Whitney  test was used  for  comparison between 


















1.  New  evidence  of  neuroprotection  by  lactate  after  transient  focal  cerebral  ischaemia: 




This  work  was  carried  out  mainly  by  Dr.  Carole  Berthet  and  is  a  continuation  of  the  work 
published by our group  in 2009 describing  the neuroprotective effect of  intracerebroventricular 
(ICV)  injection of  lactate after tMCAO (Berthet et al., 2009). In this study, we went on to show a 
long  term  neuroprotective  effect  after  ICV  administration  of  lactate  that  yielded  smaller 
hemispheric  atrophy  14  days  after  tMCAO  and  better  neurological  outcome  in  the mice  that 
received  lactate  compared  to  control mice.  Considering  the  aim  of  translation  of  lactate  as  a 
neuroprotectant  in clinics we decided to test a more suitable route of  lactate administration for 
clinical practice and tested intravenous (IV) lactate administration. We showed that IV injection of 
lactate was  also  able  to exert protection by  significantly decreasing  the  lesion  size  at48h  after 
tMCAO  (13.7  ±  12.2  mm3,  n=12  vs.  29.6  ±  25.4  mm3,  n=12,  p<0.05)  and  attenuating  the 
neurological deficit in the mice that received the IV treatment (median=1, min=0, max=2.5, n=12) 
compared to control mice (median=1.5, min=1, max=8, n=12, p<0.05).  
My personal contribution  to  this work  involved showing by  immunohistochemistry analysis  that 
there was a decrease  in neuronal death  in the  lesion site (striatum)  in mice treated with  lactate 
and by measuring the acid‐base status that IV injection of lactate did not promote an increase in 
the blood pH (7.34 ± 0.09 lactate vs. 7.29 ± 0.07 control, n=4),pCO2 (40.75 ± 4.81 lactate vs. 38.97 




















f and 2  (2a‐f)  respectively),  the  cortex  (row 3, 3a‐f) and  the  striatum  (row 4, 4a‐f)  revealed by 




Figure  11.  Confocal  visualization  of  HCA1  receptor  expression,  colocalization  with  neuronal 
markers. Using an antibody against neuronal cells, we confirmed with immunohistochemistry the 
localization  of  the  HCA1  receptor  is  mainly  in  neurons.  The  brain  structures  analyzed  were 










1a 1b 1c 1d 1e 1f 
2a 2b 2c 2d 2e 2f 
3a 3b 3c 3d 3e 3f 
4a 4b 4c 4d 4e 4f 























astrocytes.  Using  an  astrocyte  marker  we  did  not  observe  by  immunohistochemistry  co‐ 
localization of  the HCA1  receptor with  reactive  astrocytes.  The brain  structures  analyzed were 




To  evaluate  whetherHCA1  receptor  expression  was  altered  at  different  time  points  after30 
minutes  tMCAO we  evaluated  the HCA1  total  protein  expression  on Western  blots  in  protein 
extracts from hippocampus, cerebral cortex and striatum at 1, 3, 8, 24 and 48 hours after tMCAO 
in collaboration with the group of Prof. Pellerin from the Physiology department of the University 
of  Lausanne.  Normalization  of  ischemic  hemisphere  was  performed  against  the  contralateral 
hemisphere. Results at 1, 3, 8 and 48 hours did not  reveal  significant differences between  the 
three brain structures investigated (Table 3). 
DG 
2a 2b 2c 
Cortex 
3a 3b 3c 
Striatum 
4a 4b 4c 
CA1 
1a 1b 1c 






Time after 30’ tMCAO  Primary  motor  and 
somatosensory cortex
Hippocampus  Striatum 
1h  1.34 ± 0.76  1.16 ± 0.41  0.74 ± 0.28 
3h  0.93 ± 0.12  0.72 ± 0.23  1.07 ± 0.25 
8h  1.10 ± 0.15  1.13 ± 0.40  0.84 ± 0.24 
48h  1.08 ± 0.25  1.27 ± 0.25  0.82 ± 0.38 
 
 
However,  a  significant  difference  in  the  ratio  of  HCA1  receptor  expression  was  seen  in  the 
ischemic  cortex  after 24 hours  (1.2 ± 0.2, p < 0.05  vs.  contralateral  cortex;  figure 8)  and  even 
though  there  is  neuronal  loss  in  the  lesion  core  (ischemic  striatum)  we  did  not  observe  a 
significant decrease in HCA1 receptor expression in this structure (0.8 ± 0.3, n.s. vs. contralateral 
cortex) which might  reflect a  compensatory  increase  in HCA1  receptor expression  in  remaining 
neurons  (figure 13). An  immunohistochemistry  approach  showed  the  apparent upregulation of 




Figure  13.  HCA1  receptor  expression  is 
increased  by  ischemia.  Western  blot 
analysis  showed  an  increase  in  HCA1 
receptor  expression  24  h  after  tMCAO  in 
the  region  surrounding  the  lesion  site 
(primary  motor  and  somatosensory 
cortex),  compared  to  the  contralateral 
hemisphere.  (*p  <  0.05;  paired  t‐test 





















Diaschisis,  as  describe  in  1914  by  von Monakow,  established  that  functional  changes  in  brain 
structures  remote  from  the  site of  a  focal brain damage were processes underlying  functional 
recovery. Modern neuroimaging studies have shown  the existence of diaschisis by  reveling  that 
focal  brain  lesions  are  accompanied  by  widespread  metabolic  changes  involving  the  affected 
cerebral  hemisphere  but  extending  into  brain  areas  supplied  by  contralateral  and  cerebellar 
arteries (Feeney and Baron, 1986). In order to control that the differences observed between the 
ipsilateral  vs  contralateral  hemispheres  were  present  regardless  the  possible  changes  that 
happened  in  the  contralateral  hemisphere,  we  decided  to  compared  the  HCA1  receptor 
expression between both hemispheres and a sham cortex. We observed that even though there 












cortex),  hippocampus  and  striatum  from  30 minutes MCAO  and  sham mice.  The HCA1  values 
were  normalized  to  the  total  protein  content  values.  (*p<0.05,  ANOVA  followed  by Dunnett’s 
multiple comparison test. Sham samples n=4, MCAO samples n=7). 
 










after  ischemia.  Western  blot  analysis 
showed  no  significant  difference  in HCA1 














Based  on  this  result  and  considering  the  neuroprotective  effect  of  lactate  administered  at 
reperfusion, we decided  to  test  if  lactate administration  regulates HCA1  receptor expression by 
injecting L‐lactate  intravenously at  the beginning of  the  reperfusion period and monitoring any 
changes  in  HCA1  receptor  expression  at  24  hours  after  the  ischemic  episode.  We  found  an 
increase  in  HCA1  receptor  expression  in  both  the  ischemic  cortex  (1.57  ±  0.34,  p  <  0.04  vs. 
contralateral cortex) and ischemic striatum (1.7 ± 0.4, p < 0.05 vs. contralateral striatum) while no 
significant difference was observed  in the hippocampus. This difference was again evident when 







promoted  by  ischemia  and  enhanced  by 
L‐lactate  administration.  Intravenous  L‐
lactate  injection  lead  to  an  increase  in 


















Figure  18.  Administration  of  L‐
lactate  promoted  an  increase  in 
the  HCA1  receptor  expression  in 
the  ipsilateral  (ischemic)  cortex 
and  striatum.  Detailed  section  of 
the  ipsilateral  and  contralateral 
cortex  and  striatum,  were  an 
increased  in  the HCA1  staining  can 
be  appreciated.  Sections  were 
counterstained with  DAPI  to  show 
cell nuclei. Color code: HCA1  [red], 








in vitro model has  the advantage  that we could  further  investigate  the physiological role of  the 
HCA1 receptor upregulation observed in vivo, by applying a HCA1 receptor agonist after OGD. For 
this  purpose,  we  used  rat  organotypic  hippocampal  slices  exposed  to  an  oxygen‐glucose 





vitro  ischemic  insult.  Western  blot  analysis  showed  an 
increase in HCA1 receptor expression 48 h after OGD (**p < 















in  the  neuroprotective  effect  of  L‐lactate  after  OGD,  organotypic  hippocampal  slices  were 








mM  3‐5  DHBA,  an  HCA1  receptor  agonist, 








The  D  enantiomer  of  lactate  was  considered  a  non‐metabolized  isoform  of  lactate,  and  was 
described to act at  least as a partial agonist of the HCA1 receptor (Cai et al., 2008; Bozzo et al., 
2013). We were interested to determine if D‐lactate could exert a neuroprotective effect both in 
vitro  and  in  vivo.    To  our  surprise,  administration  of  4  mM  D‐lactate  to  rat  organotypic 
hippocampal slices directly after OGD also resulted in significantly reduced neuronal cell death in 
the CA1 region of the hippocampus 48 hours after OGD, from 29.2 ± 14.3 % to 11.3 ± 7.3 % (p < 











Figure  21.In  vitro  neuroprotection  by  D‐
lactate. Administration  of  4 mM D‐lactate 
induced  a  significant  reduction  in  cell 
death,  assessed  by  PI  staining,  48  h  after 
treatment  (*p  <  0.05,  One  way  ANOVA 
Kruskal‐Wallis  followed by Dunn’s multiple 





We  then  tested  D‐lactate  in  vivo  by  intravenous  administration  of  1  µmol/g  D‐Lactate  after 
tMCAO. Mice with  satisfactory  ischemia  (rCBF < 20% of baseline)  and  reperfusion  (rCBF  above 
50%  of  baseline)  received  a  single  intravenous  administration  of  D‐lactate  or  vehicle,  10‐15 
minutes  after  the  silicon‐coated  monofilament  was  removed  allowing  reperfusion.  A  single 








D‐lactate.  Intravenous  injection  of  1 
µmol/g D‐lactate after 45 min tMCAO 
decreased  total  infarct  volumes 
measured  48  h  after  ischemia  (*p  < 

























observation  of  neuroprotection  exerted  by D‐lactate  in  both  our  in  vivo  and  in  vitro  ischemic 
models, prompted us to study a bit further this issue in the rodent brain in collaboration with the 
group of Prof. Bruno Weber at  the Neuroscience centre of  the University Hospital of Zürich  to. 
They  previously  described  L‐lactate  metabolism  using  radiolabeled  L‐lactate  to  trace  its 












It  has  been  previously  described  that  glucose  administered  before  ischemic  stroke  exerts  a 
detrimental  effect  resulting  in  increased  lesion  size  in  a  rat model  of  global  cerebral  ischemia 
(Schurr et al., 2001). As glucose  is the main energetic substrate of the brain, we decided to test 
the effect of glucose administration after OGD  in vitro. Administration of glucose to organotypic 






Administration  of  two  doses  of  glucose  did  not 
protect against  ischemic damage and was  indeed 
detrimental.  Cell  death  was  assessed  by  PI 
staining  48 h  after  treatment.  (One way ANOVA 






HCA1  receptor,  utilization  of  D‐lactate  as  an  energy  substrate  might  also  contribute  to  its 
beneficial  effect  in  ischemia.  Therefore, we  explored  the  specificity  of  its metabolic mode  of 







of  pyruvate  in  different models  of  cerebral  ischemia  (Lee  et  al.,  2001;  Ryou  et  al.,  2012).  In 





Figure  25.Administration  of  pyruvate  after 
OGD.  Administration  of  10  mM  pyruvate 
directly  to  the medium  after  1  h OGD  in  rat 
organotypic  hippocampal  slices  was  able  to 
protect  against  ischemic  damage.  Cell  death 
was  assessed  by  PI  staining  48  h  after 






administration at  reperfusion after 30 minutes  tMCAO  induced only a  slight  reduction  in  lesion 
size (p = 0.4), from 91.9 ± 53.6 mm3 (control group, n= 7) to 64.6 ± 53.4 mm3 (pyruvate, n=5) 48 
hours after  ischemia. Due  to the  inherent variability of the model our experiment was however 
underpowered to detect a significant neuroprotective effect (the sample size calculation using an 
alpha  error  of  5%  and  a  beta  error  of  50%  resulted  in  a  sample  size  of  21  per  group, 
www.dssresearch.com) (Figure 26). 
 
Figure  26.  Administration  of  pyruvate  after  30 
minutes  tMCAO.  Administration  of  1µmol/g 
pyruvate  intravenously  at  reperfusion  after  30 
minutes tMCAO in adult mice was not able to induce 











As both  L‐  and D‐lactate  could be  taken up  and metabolized  in principle by  either neurons or 
astrocytes we wanted  to determine whether  the  beneficial metabolic  effect of  lactate  in  vitro 
could be  exerted  via  its use by  astrocytes.  For  this purpose, we made use of  acetate which  is 
known to be specifically taken up and used as an energy substrate by astrocytes (Waniewski and 
Martin, 1998). However,  the addition of different  concentrations of acetate  (0.13, 0.2, 4 and 8 





OGD.  Administration  of  various  doses  of 
acetate  did  not  protect  against  ischemic 
damage.  Cell  death  was  assessed  by  PI 
staining  48  h  after  treatment.  (One  way 





To  further  investigate  lactate  being  used  as  a  metabolic  substrate  in  the  post‐ischemic 
neuroprotection,  we  decided  to  test  the  administration  of  the  monocarboxylate  transporter 
inhibitor  4‐CIN  to  organotypic  hippocampal  slices  cultures  prior  to  oxygen  and  glucose 
deprivation, and posterior application of 4mM lactate, the concentration that has shown to exert 
protection in our previous experiments. If lactate is not able to enter the cells to be metabolized, 













hippocampal  slice  cultures.  Administration  of 
various doses of 4‐CIN  showed a  cytotoxic effect 
by increasing the percentage of cell death without 












(Part of  these  results have been  submitted  for publication  in  Journal of Cerebral Blood 
Flow  and  Metabolism  as:  A  probable  dual mode  of  action  for  both  L‐  and  D‐  lactate 

















The ANLS hypothesis has been  severely criticized and one of  the main criticisms  is provided by 
Simpson  et  al.,  who  proposed  an  alternative,  mathematical  model  whereby  taking  into 
consideration  concentration and  kinetic  characteristics of  the blood brain barrier and neuronal 
and glial transporter proteins (GLUT1 – 3 and MCT1 – 2), they concluded that  is  in the neuron – 
and not in the astrocyte‐ that glucose gets metabolized and the astrocyte is the chief exporter of 
lactate  (Neuron‐Astrocyte  lactate  shuttle,  NALS)  (Simpson  et  al.,  2007).  This  report  somehow 
revived  the  long  fight between  scientists  that  support or discard  the ANLS hypothesis, claiming 
besides the direction of  lactate flux, the overall contribution of  lactate to cerebral metabolism  is 
small (Fillenz M, 2005; Mangia et al., 2009; Dinuzzo et al., 2010; Jolivet et al., 2010; Mangia et al., 




mentioned  though,  that a closer analysis performed by Schurr and Gozal  (2012) estimated  that 
since the  lactate basal  level before stimulation was 1.19 mM and that of glucose was 2.60 mM, 
and  that  stimulation  prompted  a  fall  of  lactate  levels  of  0.08  mM  and  on  glucose  levels  of 
0.36mM. At  first sight  it would appear  that a significant portion of  the energy  required  for  this 
activation is supplied via glycolysis as 0.36mM glucose were consumed, while a smaller portion of 
that  energy  is  supplied  via  aerobic  consumption  of  lactate,  since  only  0.08mM  of  the 
monocarboxylate were consumed. These quantities, however, could be misleading since 0.36mM 
glucose  produces  a  net  amount  of  0.72  mM  ATP  (1  mol  of  glucose  produces  2  mol  of  ATP 
glycolytically), while 0.08 mM lactate produces 2.72 mM ATP (1 mol of lactate produced ๞34 mol of 
ATP  via  the mitochondrial  tricarboxylic  acid  (TCA)  cycle). Consequently,  the  “small”  amount of 
lactate  consumed  upon  the  first  stimulation  actually  produced  3.8  times more  ATP  than  the 
amount produced by the consumption of glucose upon the first stimulation. 
According  to  Avital  Schurr,  the  main  point  of  the  long  discussion  appears  to  be  the 






therefore  prompting  several  groups  to  execute  research  and  invest  effort  into  proving  that 
concept wrong,  trying  to  keep  the  “most  important brain energy  substrate”  crown  for  glucose 
(Schurr, 2014). Glucose is the main energy substrate for brain activity and it is not the focus of this 
thesis  to  argue  against  this  concept.  The  focus  instead  is  to  show  that  lactate  is  an  important 
molecule not only  for a series of physiological processes but  that  it can exerts neuroprotectant 
effects, and to investigate the possible mechanism of action.  
Since McIlwain’s description  in 1953  that  lactate  can act as an energy  substrate  to  sustain  the 
metabolic  rate  of  the  brain  (McIlwain  H,  1953)  many  efforts  have  been  made  and  different 




1997; Fellows et al. 2003).  Lactate has also been  involved  in  important physiological processes 
such as memory consolidation as well as long‐term memory formation (Suzuki et al. 2011) and it 
was  shown  using  a  transient  global  cerebral  ischemia  model  in  rats  and  a  monocarboxylate 
transporter inhibitor that brain lactate is essential to improve post ischemic outcome(Schurr et al. 
2001).   
Lactate has been shown as  in  important molecule  involved  in  the physiological  functions of  the 
central nervous system not only in lactate‐neuron interactions, but has also been described to be 
important  for  the  metabolic  homeostasis  of  other  cell  types  such  as  oligodendrocytes. 
Oligodendrocytes  consume  more  lactate  than  neurons  in  culture,  possibly  due  to  use  as  a 
metabolic substrate and as a precursor to build carbon skeletons (lipid synthesis) (Sánchez‐Abarca 
et  al.,  2001).  Furthermore,  Rinholm  et  al.,  showedthat  lactate  can  be  taken  up  by MCT1  and 
support  oligodendrocyte  development  and  myelination  when  glucose  levels  are  low,  such  as 
during the early postnatal period (Rinholm et al., 2011). Funfschilling et al., used a transgenic mice 
approach to show that enhanced glycolysis increases production and release of lactate, pyruvate 
and  acetyl‐coenzyme‐A  (CoA)  from  oligodendrocytes  that  can  supply  glycolysis  products  to 










conditions  as  well  as  the  importance  of  a  working  transport  system.  Nevertheless,  in  some 
situations where oxygen and glucose are restricted,  lactate has been shown to have a beneficial 




As mentioned above  it  is well known that the monocarboxylate transporter family  is responsible 
not only  for  lactate’s  fluxes  from different cell  types but also  those of other monocarboxylates 
such as pyruvate, acetate and ketone bodies. The monocarboxylate  transporters show selective 
expression  in different cell  types as well as  transporting  the monocarboxylates  from one cell  to 
another  with  different  affinities  (Pierre  and  Pellerin,  2005).  Considering  this  information,  the 
recent work describing lactate acting as a signaling molecule in the central nervous system, either 





focused on  the presence of  the HCA1  receptor  in  the  central nervous  system and  the  changes 
observed  in  its  expression when mice were  subjected  to  ischemia. We  also  used  the  lactate 
enantiomer D‐lactate, since it has been described to be transported by the MCTs and also acts as 
a weak  agonist  of  the HCA1  receptor.  In  the  second  part  of  this work, we  used  pyruvate  and 
acetate  to  assess  neuroprotection  after  in  vitro  ischemia  since  these  monocarboxylates  are 





three  brain  regions  (cortex,  hippocampus  and  striatum)  and  our  results  show  that  the  HCA1 







modulated  by  ischemia  and  that  L‐lactate  seems  to  be  a  signal  for  the  induction  of  its  own 
receptor.  
One interesting feature of the modulation of the HCA1 receptor 24h after ischemia is that without 
exogenous  lactate stimulation  there appears  to be an  increase  in  the cortex  that surrounds  the 
lesion site, probably in a region where the detrimental mechanisms of neuronal death can still be 
reversed. Another interesting observation is that in the ischemic striatum, where the lesion core is 
located,  there  is no difference  in  the HCA1  receptor expression  compared  to  the  contralateral 
hemisphere. As mentioned,  the HCA1  receptor appears  to be expressed mainly  in neurons and 
the fact that there  is no detectable change  in  its expression ratio  in the  lesion core might be an 
indirect  indication  that  HCA1  receptor  is  over‐expressed  in  the  few  remaining  neuronal  cells 
located  in  the  ischemic  core.  However, with  the  information we  have we  cannot  affirm  that 
lactate  accumulation  following  ischemia  is  in  fact  the  responsible  for  the  enhancement  of  the 
HCA1 receptor observed after 24 hours of reperfusion.  











the HCA1  receptor,  to  the best of our  knowledge  the  results  shown  in  this  thesis  are  the  first 
evidence that the HCA1 receptor  is  involved  in the neuroprotective effects of  lactate  in  ischemic 
stroke.  This  is  an  important  observation  since  it  highlights  the  necessity  to  consider  that  the  
effects  of  lactate  in  the  central  nervous  system  might  not  be  completely  abolished  when 









Here  it  is  important  to  mention  the  recent  work  of  Shen  et  al.,  who  showed  that  a  vector 
containing  a  green  fluorescent  protein  coupled with  the GPR81  (HCA1)  receptor  (GFP‐GPR81) 
transfected  into mouse  neuroblastoma  neuro‐2a  (N2A)  cells  aggravated  the OGD‐induced  cell 
death  compared  to  control  cells.  In  this  work  they  used  3‐hydroxy‐butyrate  (3‐OBA)  as  an 
antagonist  of  the  HCA1  receptor  (GPR81)  and  observed  protection  (decreased  the  cell  death) 
when  this ketone body was applied  to cells  subjected  to OGD. Similar  results were obtained  in 
vivo when 3‐OBA was  injected  intracerebroventricularly at the onset of permanent MCAO and a 
reduction  in the  lesion size was observed (Shen et al., 2014). The work  is  intriguing  in that they 
used a ketone body (3‐OBA) as antagonist of the HCA1 receptor, knowing that ketone bodies are 
agonists of another members of the hydroxycarboxylic acid receptor  family,  includingHCA2, and 
that  it has been  recently described  that activation of  the HCA2  receptor by ketone bodies and 
nicotinic  acid  exerts  protection  decreasing  infarct  volume  and  activating monocytes  and  /  or 
macrophages  (Rahman  et  al.,  2014).  Therefore  they  cannot  rule  out  the  possibility  that  their 
results are due to activation of the HCA2 receptor  instead of antagonism of the HCA1 receptor. 
Nonetheless,  the model used  in  the work performed by  Shen et  al.,  is not  the  same  as  in our 
experiments (30 minutes ischemia vs permanent ischemia; organotypic hippocampal slice cultures 
vs neuronal cultures  transfected with HCA1 receptor) and our results provide  the  first evidence 




In  the  literature,  D‐lactate,  the  enantiomer  form  of  lactate,  has  been  described  on  several 
occasions to be a non‐metabolize (inactive) enantiomer. Nevertheless, if we look more carefully it 
has been described  that D‐lactate can also be  transported by  the monocarboxylate  transporter 
family (Kang KP et al., 2006) although with less affinity than L‐lactate and also isolation of human 





that D‐lactic acidosis risk  increases  for several reasons such as  the presence of a malabsorption 







colonic motility  that would allow nutrients  into  the colon  to undergo bacterial  fermentation.  In 
fact,  it  has  been  reported  that  healthy  infants  and  adults  are  able  to  metabolize  D‐lactate 
(Haschke‐Becher E et al., 2000; Uribarri et al., 1998; Talasniemi JP et al., 2008) and that impaired 






In  our  experiments,  we  found  that  neuroprotection  was  also  achieved  when  D‐lactate  was 




the  rodent  brain  and  metabolized  to  CO2  only  marginally  less  than  the  previously  reported 
fraction of CO2 produced by L‐lactate (Wyss et al., 2011; Appendix, figure 21). So  its metabolism 
might explain  the neuroprotection we observed however, other observations by several groups 
show  that D‐lactate exhibits at  least a partial agonist activity on  the HCA1  receptor  (Cai et al., 
2008; Bozzo et al., 2013;  Liu et al., 2009; Ahmed et al., 2010). Therefore, we  cannot  conclude 
using D‐lactate protection  if neuroprotection  takes place as a result of  lactate being used as an 
energy substrate or acting through the HCA1 receptor.  
Considering that lactate is transported by MCTs, we decided to try another approach by blocking 
the MCTs with  α‐cyano‐4‐hydroxy‐cinnamate  (4‐CIN)  a  compound widely  used  to  inhibit MCT 
function in vitro and in vivo (Erlichman et al., 2008; Tang et al., 2014; Schurr et al., 2001). The first 
step of  this experiment was  to establish a  safe concentration of 4‐CIN  that elicited blockage of 
MCTs but did not result in toxicity of the cultures. Unfortunately, these toxicity assays took longer 










The  detrimental  effects  observed  with  glucose  administration  after  OGD  to  organotypic 
hippocampal  slice  cultures  are  in  line with previous observations  reported  in  the  literature.  In 
1977  Myers  and  Yamaguchi  found,  by  serendipity  that  administration  of  glucose  (instead  of 
saline) to monkeys before a 14 min cerebral  ischemia resulted  in a worse neurological outcome 
(Myers and Yamaguchi, 1977). This finding, confirmed by many groups in basic science prompted 




ischemic  lactic acid  levels. Regardless  this  long standing dogma,  lactate might have a safe “way 
out”  as  the  cause  of  the  observed  detrimental  effects.  Schurr  et  al.,  described  that  glucose 
administered 2h before inducing ischemia had a beneficial effect lowering the degree of neuronal 
damage, and that glucose administered from 15 to 60 minutes before  ischemia was detrimental 
exacerbating  neuronal  damage  in  comparison  to  the  control  rats. When  lactate  transport was 
blocked  with  the  MCT  inhibitor  4‐CIN  administered  concomitantly  with  glucose  2h  before 






In  the  central nervous  system, pyruvate  is  transported mainly by MCT1in astrocytes and blood 
vessels and MCT2  in neurons  in  the direction of  the concentration gradient  (Pierre et al., 2002; 
Pellerin  et  al.,  2005).  As mentioned  above,  lactate  can  be  converted  to  pyruvate  by  lactate‐
dehydrogenase to fuel the Krebs cycle and therefore be used as an energetic substrate. Trying to 
elucidate  the  impact  that  the  metabolic  pathway  might  have  on  the  neuroprotective  effects 
observed with the administration of lactate, we administered pyruvate in vitro after 1h OGD and 
in  vivo  at  reperfusion  after  30  minutes  MCAO.  Evidence  supporting  ametabolic  effect  is  the 
protection we  obtain with  the  administration  of  10 mM  pyruvate  in  vitro,  although we  fail  to 
obtain protection in vivo when pyruvate was administered at reperfusion after 30 minutes MCAO. 













Nevertheless,  in  agreement  with  our  observations  other  groups  have  described  the  in  vitro 












MCT1  and metabolized  in  astrocytes  (Waniewski  and Martin,  1998; Wyss  et  al.,  2009). During 
ischemia  it was observed  that  14C‐acetate  uptake  is decreased  as  early  as  3 minutes  after  the 
onset of  ischemia. The degree of reduction  in 14C‐acetate uptake correlates with the severity of 
ischemia which, according to Hosoi et al., relates to the depression of glial metabolism (Hosoi et 





of the doses that we applied. Even though there  is an  increased energy demand  in neurons and 
astrocytes subjected to ischemic insult, this result suggests that energy supply to astrocytes is not 
enough to exert neuroprotection after an ischemic insult. It should be noted that using an in vitro 
assay  of  ligand‐induced  35S‐GTPγS  binding with membranes  from  CHO  cells  expressing  human 































The data obtained  so  far point  to  the possibility  that  lactate,  independently of  the enantiomer 
type,  confers  neuroprotection  after  ischemia  perhaps  by  two  mechanisms:  One  is  through 
classical metabolic pathways providing an alternative energy supply to deprived neurons and the 






In  order  to  get  a  clearer  picture  of  the  role  that  the  HCA1  receptor might  be  playing  in  the 
neuroprotective effects of lactate, I envisage a knock down approach of the protein either in vitro 
using si‐RNA or  in vivo using the HCA1  ‐/‐ mice produced by the group of Stefan Offermanns  in 
Germany. Unfortunately I did not have the time to perform these experiments but would expect 
that  HCA1‐/‐  mice  subjected  to  tMCAO  would  still  show  some  protection  after  lactate 
administration  since  lactate  should  still  be  able  to  be  used  as  an  energy  substrate.  In  these 
transgenic mice it would also be interesting to analyze the expression of the different MCTs since 
preliminary  analysis of HCA1  and MCTs  expression  in wild  type CD1 mice  subjected  to 30 min 
MCAO and supplemented with either L‐lactate or PBS at reperfusion have shown the existence of 
some  sort  of  counter  regulation  between  MCT2,  the  monocarboxylate  transporter  expressed 
mainly in neurons and reputedly in charge of lactate’s import into neurons, and HCa1 expression 
in  the  different  brain  structures  analyzed  (Appendix,  figure  22  and  23). When  analyzed  at  the 
same time points and tissue samples used to analyze HCA1 receptor expression, MCT2 showed no 
difference  in  the  ratio  of  MCT2  expression  in  the  ischemic  hemisphere  compared  to  the 
contralateral  hemisphere  in  mice  subjected  to  30  minutes  MCAO.  Interestingly,  L‐lactate 









In  order  to  elucidate  the  importance  of  lactate  as  metabolic  substrate  in  the  post‐ischemic 
outcome,  lactate  transport  could  be  blocked  in  vitro with  4‐CIN  supplemented  in  the medium 


























Figure  29.  D‐lactate  metabolism.  a)  Schematic  of  the  biochemical  pathways  involved  in  the 
degradation of lactate and the proposed interpretation of the rate constants K1 and k2 which are 
mathematically  defined  by  the  one‐tissue  compartment  model  used  for  1‐11C‐D‐lactate  data 
analysis. b) Measured radioactivity concentration in the brain (open circles), model fit (black line) 
and arterial input curve (gray line). The inset displays the residuals of the fitting to the one‐tissue 
compartment model.  Equal  distribution  around  the  neutral  line  supports  the  adequacy  of  the 
applied  model.  c)  Fraction  of  native  radiolabeled  lactate  over  40  minutes  after  intravenous 
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logical deficits at 7 days (median = 0, min = 0, max = 3, n = 7 
vs. median = 2, min = 1, max = 4.5, n = 5, p  ! 0.05) and 14 days 
after ischaemia (median = 0, min = 0, max = 3, n = 7 vs. me-
dian = 3, min = 0.5, max = 3, n = 7, p = 0.05). Reduced tissue 
damage was demonstrated by attenuated hemispheric atro-
phy at 14 days (1.3  8 4.0 mm 3 , n = 7 vs. 12.1  8 3.8 mm 3 , n = 
5, p  ! 0.05) in lactate-treated animals. Systemic intravenous 
lactate administration was also neuroprotective and attenu-
ated the deficit (median = 1, min = 0, max = 2.5, n = 12) com-
pared to vehicle treatment (median = 1.5, min = 1, max = 8, 
n = 12, p  ! 0.05) as well as the lesion volume at 48 h (13.7  8 
12.2 mm 3 , n = 12 vs. 29.6  8 25.4 mm 3 , n = 12, p  ! 0.05).  Con-
clusions: The beneficial effect of lactate is long-lasting: lac-
tate protects the mouse brain against ischaemic damage 
when supplied intracerebroventricularly during reperfu -
sion with behavioural and histological benefits persisting 2 
weeks after ischaemia. Importantly, lactate also protects af-
ter systemic intravenous administration, a more suitable 
route of administration in a clinical emergency setting. These 
findings provide further steps to bring this physiological, 
commonly available and inexpensive neuroprotectant clos-
er to clinical translation for stroke. 
 Copyright © 2012 S. Karger AG, Basel 
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 Abstract 
 Background: Lactate protects mice against the ischaemic 
damage resulting from transient middle cerebral artery oc-
clusion (MCAO) when administered intracerebroventricular-
ly at reperfusion, yielding smaller lesion sizes and a better 
neurological outcome 48 h after ischaemia. We have now 
tested whether the beneficial effect of lactate is long-lasting 
and if lactate can be administered intravenously.  Methods: 
 Male ICR-CD1 mice were subjected to 15-min suture MCAO 
under xylazine + ketamine anaesthesia. Na  L -lactate (2 l of 
100 mmol/l) or vehicle was administered intracerebroven-
tricularly at reperfusion. The neurological deficit was evalu-
ated using a composite deficit score based on the neuro-
logical score, the rotarod test and the beam walking test. 
Mice were sacrificed at 14 days. In a second set of experi-
ments, Na  L -lactate (1   mol/g body weight) was adminis-
tered intravenously into the tail vein at reperfusion. The neu-
rological deficit and the lesion volume were measured at
48 h.  Results: Intracerebroventricularly injected lactate in-
duced sustained neuroprotection shown by smaller neuro-
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 In the neurovascular unit, astrocytes line cerebral cap-
illaries with their end feet and interact closely with neu-
rons at the synapses. Brain activation is coupled to glu-
cose uptake from the blood stream, which is likely to in-
volve astrocytes due to the spatial organization of the 
neurovascular unit. Lactate, a product of anaerobic gly-
colysis, can be shuttled from astrocytes to neurons and 
used as an efficient energy substrate  [1] . Lactate transport 
from astrocytes to neurons plays a physiological role as it 
was recently shown that this transport is critical for long-
term memory  [2] . Lactate shuttling also has an important 
role in physiopathological events  [3, 4] . Lactate protects 
neural tissue against excitotoxicity as it attenuates neuro-
nal death induced by intracortical glutamate injection  [3, 
5] . Based on the knowledge of this beneficial role of lac-
tate, we recently demonstrated that lactate could also pre-
vent ischaemic neuronal death in vitro in hippocampal 
slice cultures subjected to oxygen and glucose depriva-
tion  [6] and in vivo, intracerebroventricular lactate injec-
tion after transient middle cerebral artery occlusion 
(MCAO) in mice attenuates both the lesion volume and 
the neurological deficit 2 days after ischaemia. We now 
show the effect of lactate neuroprotection on outcome at 
later time points as well as demonstrate a beneficial re-
sponse at 48 h with intravenous administration. Lactate 
is a natural and easily available substance and our recent 
results are critical steps for its translation to clinical 
stroke patients.
 Materials and Methods 
 Transient MCAO in the Mouse 
 All animal experiments were conducted according to Swiss 
guidelines for animal experimentation and approved by the vet-
erinary authority. Male ICR-CD1 mice (body weight 26–35 g, 
Charles River, L’Arbresle, France) were anaesthetized by intraper-
itoneal injection of 8 mg/kg xylazine (Rompun 2%, Bayer, Zurich, 
Switzerland) and 100 mg/kg ketamine (Ketanarkon 100, Streuli 
Pharma, Uznach, Switzerland). At 0 h, ischaemia was induced by 
inserting a silicone-coated 8-0 filament (Doccol Corp., Redlands, 
Calif., USA) through the left common carotid artery into the in-
ternal carotid artery  [6, 7] . The filament was withdrawn after 15 
min for reperfusion. Regional cerebral blood flow (rCBF) was 
measured by laser Doppler flowmetry (Periflux 5000, Perimed, 
Stockholm, Sweden) with a flexible probe fixed on the skull, 1 mm 
posteriorly and 6 mm laterally from the bregma and monitored 
throughout surgery. Rectal temperature was maintained at 37  8 
0.5    °    C throughout surgery, using a temperature control unit 
(FHC, Bowdoinham, Me., USA). Mice were administered 0.025 
mg/kg of buprenorphine subcutaneously for analgesia after sur-
gery. They were then housed overnight in an incubator at 31   °   C. 
Mice were sacrificed after 48 h or 14 days. Among intracerebro-
ventricularly injected mice, 5/18 died before the 14-day time point 
(2 died during surgery before treatment; 2 vehicle-treated mice 
died on day 4; 1 lactate-treated animal died on day 6). Among in-
travenously injected mice, 4/52 died before 48 h (1 died dur-
ing surgery before treatment; 3 vehicle-treated animals died on 
day 2). 
 Lactate Treatment 
 Two microlitres of either the 100 mmol/l Na  L -lactate (Fluka, 
Sigma-Aldrich, Buchs, Switzerland) solution corresponding to 
200 mmol/l or vehicle (1 ! PBS, pH 7.4) were randomly injected 
by a surgeon blinded to the treatment solution intracerebroven-
tricularly at reperfusion into the left lateral ventricle (0.9 mm lat-
erally, 0.1 mm posteriorly, 3.1 mm deep from the bregma  [6, 8] ) 
using a Hamilton syringe (Hamilton Company, Bonaduz, Swit-
zerland).
 Five microlitres per gram of body weight of Na  L -lactate solu-
tion (200 mmol/l) or vehicle solution were injected by a surgeon 
blinded to the treatment solution intravenously (tail vein) admin-
istered at reperfusion using a 1-ml syringe with a 25-gauge needle 
and a mouse restrainer (Braintree Scientific Inc., Braintree, Mass., 
USA).
 Lesion Volume Measurement 
 The lesion volume was calculated by multiplying the distance 
between sections by the lesion area, measured on 20-  m-thick 
cryostat sections stained with cresyl violet and by an examiner 
blinded to the treatment group. The hemispheric atrophy was cal-
culated by subtracting the volume of the hemisphere which suf-
fered ischaemic injury from the unaffected hemisphere.
 Immunohistochemistry 
 Frozen cryostat brain sections were fixed with 4%  p -formal-
dehyde for 1 h at 4   °   C, washed in 1 ! PBS and incubated over-
night at 4   °   C in 1 ! PBS, 1% bovine serum albumin, and 0.1% 
Triton with neuronal nuclear antigen (NeuN) (Sigma) antibody 
(1: 300 dilution). The sections were incubated for 1 h at room 
temperature in the same buffer with anti-mouse FITC (Jackson 
ImmunoResearch Laboratories, Baltimore, Md., USA) antibody. 
Sections were mounted in Vectashield (Vector Labs, Burlin-
game, Calif., USA). Images were acquired with the Axiovision 
v4.8 software using a Zeiss Axiovision microscope (488 nm ab-
sorbance).
 Behavioural Evaluation 
 A composite neuroscore  [6, 9] was used to assess the neuro-
logical deficit, as previously described  [6] . The composite score is 
based on three tests, each with a maximum of 3 points: the neu-
roscore (0 = no observable neurologic deficit; 1 = failure to extend 
the right forepaw; 2 = circling to the contralateral side, and 3 = 
loss of walking or righting reflex); secondly, the beam walking test 
 [10] (0 = the mouse walks directly to the end of the beam; 1 = the 
mouse walks along the beam with a few slips; 2 = the mouse can-
not walk more than a few steps, and 3 = the mouse does not move); 
finally, the rotarod treadmill (UgoBasile, Comerio, Italy) test  [10] , 
i.e. the mice are placed on a rotating drum, set to accelerate uni-
formly from 4 to 40 rpm, and their latency to fall from it is re-
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gery, with 2 trials for each session. The test was then performed at 
different time points after MCAO, and the better of the 2 con-
secutive trials was selected. Points were attributed on the basis of 
performance expressed as a percentage of the best performance 
before ischaemia (0 point: 90–100% and then 0.5 point for each 
15% decrease)  [6] .
 Exclusion Criteria 
 The surgeon applied strict exclusion criteria before statistical 
analysis: mice with temperature outside the 36.5–37.5  °  C limit, an 
rCBF above 20% of baseline during ischaemia or below 50%, 10 
min after reperfusion. In intravenously injected mice, those mice 
for which the surgeon doubted the quality of injection were ex-
cluded. In total, 1 mouse out of 13 was excluded from the intra-
cerebroventricular group and 24/48 from the intravenous group.
 Brain Lactate Measurements 
 Mice underwent cerebral ischaemia followed by lactate or ve-
hicle injection (intravenous or intracerebroventricular). Thirty 
minutes after injection, animals were sacrificed by intracardiac 
PBS perfusion for 2 min to remove blood. Brains were isolated and 
frozen in liquid nitrogen vapour.
 Brain lactate was measured in each hemisphere by an enzy-
matic-spectrometric protocol in which lactate contained in the 
sample is incubated with lactate dehydrogenase (14 U/ml) and
3 mmol/l NAD in glycine-semicarbazide 0.2 mol/l buffer, pH 10. 
NADH resulting from the reaction is measured by its absorbance 
at 340 nm  [11, 12] . 
 Blood Gas Analysis 
 Mice were injected intravenously with either lactate or PBS. 
Arterial blood (125   l) was withdrawn from the carotid artery 
15–26 min after injection and collected in Clinitubes (Radiome-
ter, Denmark). Samples were analysed for blood gases and lactate 
in a Radiometer ABL800 Flex machine. 
 Statistics 
 Parametric data were presented as mean  8 standard deviation 
and scores as median, minimum, maximum. Statistical analyses 
were carried out using the non-parametric two-tailed Mann-
Whitney test (Instat, Graphpad, La Jolla, Calif., USA). A probabil-
ity of 0.05 or less was considered significant.
 Results 
 Intracerebroventricular Injection of Lactate 
Attenuates Ischaemia-Induced Hemispheric Atrophy 
and Improves the Functional Outcome 14 Days after 
Transient MCAO in Mice 
 To extend our previous observation of neuroprotec-
tion with intracerebroventricular injection of lactate after 
mouse MCAO, we subjected mice to 15 min transient 
MCAO under xylazine + ketamine anaesthesia. In this 
model, the striatal and small cortical lesions seen at early 
time points were even smaller at 14 days in both groups. 
Therefore, lactate treatment did not appear to induce a 
significant reduction in lesion size at this late time point 
(5  8 3 mm 3 , n = 7 vs. 8  8 3 mm 3 in vehicle treatment,
n = 5, p = 0.17) ( fig. 1 a). Although the small size of lesions 
may have a confounding effect, reduced tissue damage in 
lactate-treated mice was demonstrated indirectly by at-
tenuated hemispheric atrophy (1  8 4 mm 3 , n = 7, vs. 12 
 8 4 mm 3 , n = 5, p = 0.048) ( fig. 1 b). Very convincing re-
sults were obtained by looking at the neurological im-
pairment detected by an increase in the composite behav-
ioural outcome score, peaking at 2 days and with partial 
recovery at 7 and 14 days after MCAO. Lactate treatment 
induced a sustained neuroprotection attested by smaller 
neurological deficits at 2 days (median neuroscore = 1.5, 
min = 1, max = 3.5, n = 6 vs. median = 4.75, min = 1.5, 
max = 7.0, n = 6 in vehicle-treated animals, p = 0.036), 7 
days (median = 0, min = 0, max = 3, n = 7 vs. median = 
2, min = 1, max = 4.5, n = 5, p = 0.028) and 14 days after 
ischaemia (median = 0, min = 0, max = 3, n = 7 vs. me-
dian = 3, min = 0.5, max = 3, n = 7, p = 0.05) ( fig. 1 c). To 
evaluate delayed neuronal loss, we performed immuno-
histochemistry with an antibody against NeuN in brain 
slices from mice 14 days after 15 min MCAO and injected 
with either PBS ( fig. 1 d) or lactate ( fig. 1 e). The ischaemic 
lesion corresponds to a region of reduced intensity of 
NeuN staining compared to the contralateral hemisphere 
in both treatment groups, demonstrating neuronal loss at 
this delayed time point. 
 There was no difference in temperature, body weight 
and rCBF during surgery and reperfusion between the 
groups.
 Lactate Injected Intravenously at Reperfusion 
Attenuates both the Lesion Volume and Neurological 
Deficit 48 h after Transient MCAO in Mice 
 Early treatment to halt the progression of ischaemic 
damage is very important in acute stroke, hence the im-
portance of a practical and quick route of administration 
for a medication. We therefore tested intravenous injec-
tion of lactate into the tail vein at reperfusion. In healthy 
human brains, lactate injected intravenously (0.75–3 
  mol/g) was shown to be metabolized. Lactate adminis-
tered intravenously was also shown to protect the human 
brain against intracranial hypertensive episodes in se-
vere traumatic brain injury  [13–15] . We tested doses of 1 
and 3   mol/g in a preliminary experiment (injection of 
3   mol/g was toxic and led to the death of 2 mice tested). 
We compared the concentration of lactate in the target 
organ, the brain, with intracerebroventricular and intra-
venous (1   mol/g) injections and showed that tail vein 















   
   
   
   
   
   
   
   
   
   
   
   
   













































































Control (n = 5) Lactate (n = 7)














 Fig. 1. Intracerebroventricular injection of 200 mmol/l lactate in-
duces sustained neuroprotection after 15-min MCAO.  a Infarct 
size measured at 14 days after MCAO represented as mean  8 SD. 
 b Atrophy of the injured hemisphere measured at 14 days after 
MCAO represented as mean  8 SD.  c Evolution of neurologic def-
icit scores (from 0 = no deficit, to 9 = most severe deficit) up to 14 
days after MCAO, represented as medians.  d ,  e Immunohisto-
chemistry with an antibody against NeuN was performed on 
brain slices from mice 14 days after 15-min MCAO and injected 
with either PBS ( d ) or lactate ( e ). The ischaemic lesion, outlined 
in white, corresponds to a region of reduced intensity of NeuN 
staining compared to the contralateral hemisphere in both treat-
ment groups.  *  p  ^  0.05 for the Mann-Whitney test, two-tailed p 
value. Circles represent individual animals. Cx = Cortex; Cc = 
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Lactate (n = 12)Control (n = 12)b
*
 Fig. 3. Intravenous injection of 1   mol/l 
lactate/g body weight at reperfusion after 
15-min MCAO is neuroprotective.  a In-
farct size measured at 48 h after MCAO 
represented as mean  8 SD.  b Neurologic 
deficit scores (from 0 = no deficit, to 9 = 
most severe deficit) at 48 h after MCAO, 
represented as medians.  *  p  ^  0.05 for the 
Mann-Whitney test, two-tailed p value. 
Circles represent individual animals. 
 Fig. 2. Brain lactate concentration is sim-
ilar after intravenous (i.v.) injection of
1   mol/g lactate or intracerebroventricu-
lar (i.c.v.) injection of 2   l of 100 mmol/l 
lactate. Lactate concentration was mea-
sured in the ischaemic hemisphere 30 min 
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the brain lactate concentration to a comparable level (af-
ter 30 min) as an intracerebroventricular injection of
2   l 100 m M lactate, recently shown to be neuroprotec-
tive  [6] ( fig. 2 ). Experiments were done with a dose of
5   l of 200 mmol/l  L -lactate solution per gram of body 
weight, corresponding to 1   mol/g of body weight. Con-
trols received an equal volume of vehicle solution. Lac-
tate administered intravenously attenuated the lesion 
volume (13.7  8 12.2 mm 3 , n = 12 vs. 29.6  8 25.4 mm 3 , 
n = 12, p = 0.046) as well as, importantly, the neurolog-
ical deficit (median = 1, min = 0, max = 2.5, n = 12)
compared to vehicle treatment (median = 1.5, min = 1, 
max = 8, n = 12, p = 0.024) at 48 h ( fig. 3 ). These results 
show that a very practical intravenous administration of 
lactate induces neuroprotection.
 There was no difference in the temperature, body 
weight and rCBF during surgery and reperfusion be-
tween the groups. Similarly, the pH, pCO 2 , pO 2 and lac-
tate measured in the arterial blood after intravenous in-
jection were not different between the groups (data not 
shown).
 Discussion 
 In this paper, we show that the neuroprotective effect 
of lactate, now tested in a 15-min MCAO under xyla-
zine-ketamine anaesthesia, extends beyond 48 h, with 
improvement in the behavioural outcome and attenu-
ated tissue destruction with significantly less hemi-
sphere atrophy at 14 days. It is important to determine 
if neuroprotection is long-lasting as long-term neuro-
logical outcome is clinically more relevant than short-
term outcome, attested by the NINDS recombinant tis-
sue plasminogen activator study  [16] and the more re-
cent ECASS 3  [17] trial, both of which used the 
behavioural outcome at 3 months as a primary outcome 
measure.
 Cerebral ischaemia causes rapidly progressing and 
devastating tissue damage in the ischaemia territory. An 
early intervention is of critical importance to impede the 
lesion progression. This is why we needed to establish a 
clinically more feasible route of administration than in-
jection into the brain. We chose intravenous administra-
tion as it is reliable and practical in the case of stroke pa-
tients. The results presented here support the ability of 
intravenously injected lactate to cross the blood-brain 
barrier  [13, 14] and efficiently protect the brain as was 
also seen in traumatic brain injury patients, a very differ-
ent injury model  [15] . However, its mode of action re-
mains unclear. Indeed, in the case of ischaemia, lactate is 
known to increase in the brain in two waves: a first in-
crease during ischaemia due to anaerobic glycolysis and 
a second increase beginning 1 h after reperfusion and 
continuing up to 72 h  [18–20] . Lactate levels in the brain 
are thus very high during ischaemia and after reperfusion 
and consequently the addition of a small amount of lac-
tate may appear pointless. However, a careful look at the 
lactate kinetics shows that between 15 min and 1 h after 
reperfusion, lactate concentrations are back to normal 
and it is exactly at this time point that we inject lactate. 
At reperfusion, there is a huge energy demand, which 
cannot be met by glucose as ATP stores are depleted and 
glucose cannot be converted to glucose-6P for glycolysis. 
In these conditions, lactate accumulated during isch-
aemia by anaerobic glycolysis represents an ideal source 
of energy, which can explain the rapid decrease of the ac-
cumulated lactate and return to baseline in the first hour 
of reperfusion and the beneficial effect of additional lac-
tate supply at this time point.
 The second increase in lactate is not due to anaerobic 
glycolysis as it occurs after reperfusion with restored ox-
ygen supply and may be explained by the astrocyte-neu-
ron shuttle model  [1] . Astrocytes are more resistant to 
ischaemia than neurons. When neurons are dying, the 
lactate produced by surviving astrocytes cannot be con-
sumed by neurons, hence an increase in lactate. Lactate 
production could also reflect an attempt of the isch-
aemic brain to rescue its suffering neurons. In less se-
vere ischaemia, the second lactate increase occurs later, 
coinciding with a more delayed neuronal demise  [21] . 
Similarly, locating where the lactate increase occurs in 
the brain using spatial mapping by magnetic resonance 
spectroscopy 24 h after ischaemia shows a gradient with 
highest lactate concentrations in the centre of the isch-
aemic lesion correlating with the severity of tissue dam-
age  [19] .
 Another mode of action of lactate shown in traumatic 
brain injury is an attenuation of cellular swelling  [15] . The 
proposed explanation for this observation is that the in-
jected lactate solution contains both metabolizable (lac-
tate) and non-metabolizable (Na) ions. The use of lactate 
by brain cells induces an imbalance between positive and 
negative charges which needs to be compensated by an 
efflux of anions from cells, accompanied by water, thus 
counteracting the detrimental cellular swelling  [15] .
 Recent exciting results on the role of oligodendrocytes 
in enhancing axon function and neuronal survival in 
models of amyotrophic lateral sclerosis also point to-
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between oligodendroglia and neurons with lactate trans-
port from oligodendroglia to neurons  [22] . 
 In conclusion, although some aspects of its role as a 
neuroprotectant remain intriguing, lactate is an exciting 
candidate for neuroprotection in ischaemic stroke. The 
results presented here bring this natural and inexpensive 
agent closer to a translation to stroke patients.
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A probable dual mode of action for both L- and D-lactate
neuroprotection in cerebral ischemia
Ximena Castillo1, Katia Rosaﬁo2, Matthias T Wyss3,4, Konstantin Drandarov5, Alfred Buck6, Luc Pellerin2, Bruno Weber3,4 and
Lorenz Hirt1
Lactate has been shown to offer neuroprotection in several pathologic conditions. This beneﬁcial effect has been attributed to its
use as an alternative energy substrate. However, recent description of the expression of the HCA1 receptor for lactate in the central
nervous system calls for reassessment of the mechanism by which lactate exerts its neuroprotective effects. Here, we show that
HCA1 receptor expression is enhanced 24 hours after reperfusion in an middle cerebral artery occlusion stroke model, in the
ischemic cortex. Interestingly, intravenous injection of L-lactate at reperfusion led to further enhancement of HCA1 receptor
expression in the cortex and striatum. Using an in vitro oxygen-glucose deprivation model, we show that the HCA1 receptor agonist
3,5-dihydroxybenzoic acid reduces cell death. We also observed that D-lactate, a reputedly non-metabolizable substrate but partial
HCA1 receptor agonist, also provided neuroprotection in both in vitro and in vivo ischemia models. Quite unexpectedly, we show
D-lactate to be partly extracted and oxidized by the rodent brain. Finally, pyruvate offered neuroprotection in vitro whereas acetate
was ineffective. Our data suggest that L- and D-lactate offer neuroprotection in ischemia most likely by acting as both an HCA1
receptor agonist for non-astrocytic (most likely neuronal) cells as well as an energy substrate.
Journal of Cerebral Blood Flow & Metabolism advance online publication, 3 June 2015; doi:10.1038/jcbfm.2015.115
Keywords: energy metabolism; focal ischemia; lactate; neuron-glia interactions; neuroprotection
INTRODUCTION
Stroke is a frequent and often disabling disease whose early
identiﬁcation and treatment within a few hours from symptom
onset are essential. In ischemic stroke, the most common stroke
subtype resulting from an arterial occlusion, energy failure
because of lack of oxygen and glucose supply to the brain is
the central mechanism leading to neural damage. Brain meta-
bolism therefore has a critical role in the pathophysiologic
mechanisms underlying neuronal damage in stroke and for
recovery. Even though glucose is known as the brain energy
substrate par excellence, other metabolic intermediates such as
monocarboxylates including lactate, pyruvate, acetate, and ketone
bodies have been shown to be oxidized for energy production1–3
under certain conditions. Brain energy metabolism is a compart-
mentalized process involving neurons as well as astrocytes and
oligodendrocytes, with metabolic interactions between different
cell types. Monocarboxylates can be transported to and from
different cell types by monocarboxylate transporters (MCTs) with
different degrees of afﬁnity. Monocarboxylate transporters are a
family of proton-dependent carriers where MCT1, MCT2, and
MCT4 are the main MCTs in the central nervous system (CNS).
Under physiologic conditions, MCT1 is expressed in endothelial
cells, astrocytes, and oligodendrocytes, MCT4 in astrocytes, and
MCT2 is the main transporter in neurons. Under hypoxic
conditions, MCT1 and MCT2 are also expressed in activated
microglia.4–6
Beside its role as an energy substrate, lactate also acts as a
signaling molecule via the HCA1 receptor in adipose tissue and
skeletal muscle.7 Interestingly, recent work revealed the presence
of the HCA1 receptor in different brain structures, including cortex,
hippocampus, and cerebellum,8 and it has been shown that
lactate administration to cortical neurons induced speciﬁc
modulations in calcium transients frequencies in the same manner
as a speciﬁc HCA1 receptor agonist.9 HCA1 receptor involvement
has also been suggested in neurologic disorders such as cerebral
malaria.10
We have previously shown that L-lactate administration is
neuroprotective in models of cerebral ischemia both in vitro and
in vivo: it attenuated neuronal death in vitro in organotypic
hippocampal slice cultures subjected to oxygen and glucose
deprivation.11 Both, intracerebroventricular and intravenous
administration of L-lactate after transient middle cerebral artery
occlusion (tMCAO) lead to a reduction in lesion size and improved
neurologic outcome.11,12 Although it was assumed so far that
lactate exerts its neuroprotective effect by acting as a metabolic
substrate for energy-deprived neurons, the mode of action is so
far not characterized and recent data on the presence and role of
the lactate receptor HCA1 in the CNS challenges this assumption.
In the present study, we have explored both possible modes
of action, as a metabolic substrate and signaling molecule.
Understanding the mechanisms by which lactate exerts its
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neuroprotective effect is essential to adequately translate this
promising preclinical neuroprotection strategy to a clinical setting.
MATERIALS AND METHODS
All experiments were conducted in accordance with ordinance 455.163 of
the Swiss Federal Veterinary Ofﬁce and approved by the Service Cantonal
des Affaires Vétérinaires (license number VD2017.4b to LH) and the Kanton
Zürich Gesundheitsdirektion Veterinäramt (license number ZH53/2007 to
BW) (cantonal veterinary authority). The animal studies are reported
according to the ARRIVE guidelines.
Transient Middle Cerebral Artery Occlusion in the Mouse
A total of 55 male CD1 mice (body weight 26 to 35 g, Charles River,
L’arbresle, France) were housed in the animal facility of the Department of
Fundamental Neuroscience of the Université de Lausanne with 12:12 light/
dark cycle with normal illumination, in groups of 5 per cage during 1 week
for acclimatization before surgery. For experiments, mice were maintained
anesthetized with isoﬂurane (1.5% to 2% in nitrous oxide/oxygen 70%/
30%) using a face mask. Body temperature was maintained at 37.0 ± 0.5 °C
throughout surgery (FHC, Bowdoinham, ME, USA). Regional cerebral blood
ﬂow (rCBF) was measured and continuously recorded throughout the
operation in all animals by laser-Doppler ﬂowmetry (Perimed AB, Stock-
holm, Sweden) with a ﬂexible probe ﬁxed on the skull (1 mm posterior and
6mm lateral from bregma). Transient focal cerebral ischemia (30 or 45
minutes depending on the set of experiments) was induced by occlusion
of the left middle cerebral artery (MCA) with an intraarterial suture as
described elsewhere.11 Brieﬂy, the left common carotid artery and the left
external carotid artery were exposed and ligated after a ventral midline
neck incision. Ischemia was induced by inserting a silicon-coated nylon
monoﬁlament (0.17mm diameter) through the left common carotid artery
into the internal carotid artery until mild resistance was felt and a drop to
less than 20% of initial rCBF was registered. Regional cerebral blood ﬂow
was monitored and maintained below 20% of the baseline level during
ischemia. Reperfusion was considered successful if the rCBF rose above
50% of baseline. Only mice that had a drop of 80% of rCBF and accom-
plished a reperfusion of above 50% of baseline in the rCBF were included in
the study. They received 5 μL per gram of body weight of either sodium
D-lactate solution (200mmol/L), pyruvate solution (200mmol/L), or vehicle
solution (phosphate-buffered saline, PBS) injected randomly in the tail vein
at reperfusion using a 1-mL syringe with a 25-gauge needle and a mouse
restrainer (Braintree Scientiﬁc, Braintree, MA, USA). All surgeries were
performed during day-light, between 9 am and 5 pm. The surgeon was not
masked. Each mouse was considered as an experimental unit.
At the beginning of the surgery, mice were administered 0.025mg/kg
of buprenorphine subcutaneously for post-surgery analgesia. Once the
animals were awake, they were housed overnight in an incubator at 28 °C.
Behavioral Evaluation
The neurologic deﬁcit was evaluated after reperfusion and before
euthanasia, with a composite neuroscore graded for severity after surgery
(0: no observable neurologic deﬁcit; 1: failure to extend the right forepaw;
2: circling to the contralateral side, and 3: loss of walking or righting reﬂex)
as previously described11 and motor performance assessed on the Rotarod
treadmill (UgoBasile, Milan, Italy). In this test, mice were placed on the
rotating cylinder, set to accelerate uniformly from 4 to 40 rpm, and their
latency to fall was recorded before 600 seconds. The animals were trained
on two different days before surgery, with two trials in each training
session. The test was then performed 24 and 48 hours after MCAO, with
two consecutive trials for each animal. The better of the two trials was
selected. Points were attributed on the basis of performances expressed as
a percentage of the best performance before ischemia (0: 90% to 100%
and then 0.5 point for each decrease of 15% until a maximum of 5 points
for the highest neurologic deﬁcit). The behavior evaluation was assessed in
a masked manner.
Determination of Ischemic Lesion Volumes
Animals were killed 48 hours after the onset of focal ischemia and 20-μm-
thick, 720-μm-distant, coronal cryostat sections were stained with cresyl
violet for histologic determination of lesion size. Digitalized images of the
Nissl-stained tissue were acquired under a light stereomicroscope (Leica
MZ16FA, Heerbrugg, Switzerland) and the lesion area was measured using
ImageJ software (ImageJ 1.36b, National Institute of Health). Infarct volume
was calculated by multiplying the sum of the lesion areas on each section
by the distance between sections.13
Immunohistochemistry
Mice were injected intraperitoneally with a lethal dose of pentobarbital
(10mL/kg, Sigma, Buchs, Switzerland) and then perfused with 150mL of
4% paraformaldehyde (Sigma-Aldrich, St Louis, MO, USA) dissolved in
1× PBS at pH 7.4. Brains were dissected, postﬁxed overnight at 4 °C,
cryoprotected 24 hours in 30% sucrose solution (Sigma-Aldrich), and
rapidly frozen. Twenty micrometer thick coronal microtome-cryostat (Leica
MC 3050S) sections were stored in cryoprotectant (30% ethylene glycol
and 25% glycerin in 1 × PBS) at − 20 °C. For immunostaining, sections were
washed three times in 1 × PBS and blocking of non-speciﬁc binding was
achieved by incubating in 1 × PBS containing 1% bovine serum albumin,
0.1% Triton X-100, and 10% normal goat serum during 1 hour. Double
labeling was performed overnight at 4 °C in the 1 × PBS solution without
normal goat serum and different antibodies: monoclonal mouse anti-
neuronal nuclear antigen (NeuN) antibody (1:500 dilution, Sigma) or
monoclonal mouse anti-microtubule associated protein (MAP2) antibody
(1:300 dilution, Sigma) and polyclonal rabbit anti-hydroxycarboxylic acid
receptor (HCA1) (1:500 dilution; Sigma). After washing three times with
1× PBS, brain sections were incubated for 2 hours at room temperature
with the following ﬂuorescent secondary antibodies: donkey anti-rabbit
Alexa-594 (1:250, Invitrogen, Eugene, OR, USA), donkey anti-mouse Alexa-
488 (1:250, Invitrogen). After immunostaining, brain sections were
incubated for 10minutes with 4,6 diamidino-2-phenylindole (Sigma)
dissolved in 1 × PBS (1/100,000) to reveal nuclei. Preparations were then
maintained at 4 °C until observation with a Zeiss LSM 710 Quasar Confocal
Microscope (Zeiss, Feldbach, Switzerland).
Western Blotting
For protein expression experiments, young adult male mice were
subjected to 30minutes MCAO as described above and killed either at 1,
3, 8, 24, or 48 hours after reperfusion. Striatum (caudate and putamen),
primary motor, and somatosensory cortex as well as hippocampus were
collected using a rodent brain matrix (adult mouse, coronal sections, ASI
Warren, MI, USA).
Total proteins were extracted from brain tissues by cellular lysis in ice-
cold RIPA buffer (#9806, Cell Signaling, Beverly, MA, USA) supplemented
with a mixture of protease inhibitors (Complete 11257000; Roche, Basel,
Switzerland). Protein quantiﬁcation was performed with the Pierce BCA
Protein Assay kit (#23227, Thermo Fisher Scientiﬁc, Pierce, Lausanne,
Switzerland) and approximately 20 μg of proteins were denatured (95 °C)
for 5 minutes in sodium dodecyl sufate-polyacrylamide gel electrophoresis
sample buffer (60mmol/L Tris-HCl pH 6.8, 5% SDS, 6.6% glycerol, 5 mmol/L
EDTA, 5% β-mercaptoethanol, and 0.1% bromophenol blue). Samples were
separated on a 10% acrylamide gel with a 4% stacking gel using an
Electrophoresis Unit (Bio-Rad, Cressier, Switzerland). Proteins were then
electroblotted onto nitrocellulose membranes (0.45 μm; #162-0115, Bio-
Rad) using the Electrophoresis Unit. Nonspeciﬁc binding sites were blocked
for 1 hour at room temperature with a solution of Tris-Buffered-Saline
(50mmol/L Tris-HCl pH 7.5, 150mmol/L NaCl) supplemented with 0.1%
Tween-20 and containing 10% (wt/vol) skimmed milk. Blots were then
incubated overnight at 4 °C with speciﬁc primary antibodies in Tris-
Buffered-Saline 0.1% containing 1% skimmed milk: rabbit anti-mouse
GPR81-S296 (HCA1) (1:500 dilution; #SAB1300790, Sigma). Blots were
washed three times in Tris-Buffered-Saline 0.1% and subsequently
incubated 2 hours at room temperature with horseradish peroxidase-
conjugated donkey anti-rabbit IgG (#NA9340V, 1:10,000 dilution; GE
Healthcare, Glattbrugg, Switzerland). After being washed three times in Tris-
Buffered-Saline 0.1%, blots were processed using Immun-StarTMWesternCTM
Chemiluminescent Kit (#170-5070, Bio-Rad). Chemiluminescence detection
was performed with the ChemiDoc XRS System (#170-8070, Bio-Rad). Total
protein content assay was performed with the Pierce Reversible Protein Stain
kit (#24580, Thermo Fisher Scientiﬁc, Pierce) and revealed with the ChemiDoc
XRS System (#170-8070, Bio-Rad). Both types of labeling were quantiﬁed with
the ImageLab 3.0 software (Bio-Rad) and the HCA1 (GPR81) protein expression
was normalized to the total protein content.
Organotypic Hippocampal Slice Cultures
Hippocampal slice cultures were prepared as described elsewhere11 from
P8 to P10 rats (OFA Sprague Dawley, Janvier, France). Coronal hippocampal
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sections (350 μm) were cultured on sterile porous membrane units
(Millicell, Millipore, Billerica, MA, USA) in wells containing 1mL of culture
medium with D-glucose 36mmol/L, 25% horse serum, 50% minimal
essential medium (supplemented with HEPES and sodium bicarbonate;
Gibco, Paisley, UK), 25% HBSS (Hank’s balanced salt solution; Gibco), and
L-glutamine 2mmol/L (Sigma-Aldrich). Cultures were kept at 33 °C, 5%
CO2, 100% humidity for 4 days. The medium was replaced by fresh
identical medium at day 4, and then by culture medium with 15% horse
serum, 60% minimal essential medium, 25% HBSS, and L-glutamine 2
mmol/L at day 7 and 10. Experiments were conducted after 10 days of
culture.
Oxygen and Glucose Deprivation on Organotypic Hippocampal
Slice Cultures
Oxygen and glucose deprivation (OGD) experiments were performed in
serum-free low glucose medium, Dulbecco’s modiﬁed Eagle’s medium
(D5030, Sigma-Aldrich) supplemented with D-glucose 1 mmol/L and
L-glutamine 2mmol/L and equilibrated for 1 hour at 37 °C, in a humidiﬁed
hypoxic chamber (COY, Grass Lake, MI, USA) with an atmosphere of 5% O2,
5% CO2, completed by N2. Hippocampal slices were transferred into this
medium and placed into the hypoxic chamber for 1 hour. Control cultures
were kept in 60% minimal essential medium, 15% horse serum, 25% HBSS,
and L-glutamine 2 mmol/L for 1 hour at 37 °C in a humid normoxic
atmosphere.11,14 For recovery, cultures where then transferred into fresh
culture medium at 33 °C for 48 hours. Cultures were randomly treated with
either D-lactate, pyruvate, acetate (Sigma-Aldrich; diluted in 1 × PBS, pH 7),
3,5-dihydroxybenzoic acid (Sigma-Aldrich; diluted in ethanol) or an equal
volume of culture medium. Sodium D-lactate at a ﬁnal concentration
of 4 mmol/L, pyruvate at 10mmol/L, sodium acetate at 0.13, 0.2, 4, or
8 mmol/L, or 3,5-dihydroxybenzoic acid at 4 mmol/L was administered
immediately after OGD.
Assessment of Cell Death in Hippocampal Slices
Cell death was determined in the CA1 region using the ﬂuorescent viability
indicator propidium iodide. Propidium iodide was applied in each dish
(50 μg/mL) 1 hour before measurement. Propidium iodide ﬂuorescence
emission (excitation wavelength 536 nm, emission wavelength 617 nm)
was measured 48 hours after hypoxia using an epiﬂuorescence microscope
with a × 5 lens coupled to a camera (Leica). Propidium iodide images were
acquired with standardized camera settings and signal intensity was
measured with ImageJ software. After subtracting the background
ﬂuorescence on each slice, the results were expressed as a percentage
of maximal cell death obtained by submerging slices in PBS for 24 hours at
4 °C. Cell death was averaged for the four slices of each culture well. The
experimenter was not masked.
Experiments Using 11C-D-lactate in Sprague Dawley Rats
Radiotracer. The D- and L-enantiomers of 1-11C-lactic acid were produced
by a previously described radiosynthetic method, which includes
separation of racemic 1-11C-lactic acid by preparative chiral ligand
exchange high-performance liquid chromatography (HPLC). Before use,
the fractions corresponding to 1-11C-D- or 1-11C-L-lactic acid were further
puriﬁed and ﬁnally formulated as sodium salts in physiologically
acceptable sodium phosphate-buffered saline (pH 7). The chemical and
enantiomeric purity of each isolated radiolabeled enantiomer was
routinely monitored by analytical chiral ligand exchange HPLC as part of
the radiosynthesis quality control and typically revealed more than 99%
enantiomeric excess of the ﬁnal product. The speciﬁc activity at the end of
the synthesis was approximately 400 GBq/μmol. Both preparative and
analytical chiral ligand exchange chromatography were performed on
reversed-phase C18 columns (octadecyl-silica), coated with a D- or
L-penicillamine-derived chiral selector. The preparation of the chiral
selectors, the coating procedures for the HPLC columns, and the HPLC
separation conditions have been described in detail earlier.15
Surgical preparation. Surgery was performed under isoﬂurane anesthesia
(2% to 3% in air/oxygen 70%/30%) and involved the placement of an
arteriovenous shunt from the right femoral artery to the right femoral vein,
tracheotomy for mechanical ventilation, and craniotomy for the placement
of the beta scintillator. The actual experiments were performed under α-
chloralose anesthesia (44mg/kg subcutaneously). The arteriovenous shunt
was run through a coincidence scintillator (GE Medical Systems, Waukesha,
WI, USA). The online arterial sampling procedure is described in detail
elsewhere.15 In short, total radioactivity in arterial blood was continuously
recorded and was then corrected for (1) a different tracer concentration in
whole blood and plasma and (2) the build-up of labeled metabolites.
D-Lactate kinetics in the somatosensory cortex. For the measurement of
the time-course of 1-11C-D-lactate in the brain, an intracortical beta
probe was used.16,17 Twenty minutes of data were acquired at baseline
condition after injection of 200 to 300 MBq of radiotracer in 5 animals. In
one of these animals, baseline cerebral blood ﬂow was determined before
1-11C-D-lactate acquisition using 15O-H2O and the methodology described
previously.16 The ﬁrst pass extraction fraction of 1-11C-D-lactate was then
calculated using the relationship EF = K1/CBF where K1 is the transport
parameter describing (1-11C-D-lactate) transport from blood to tissue
(Figure 4A).
Kinetic modeling. Acquired radioactivity data were analyzed using the
software package PMOD (PMOD Technologies GmbH, Zürich, Switzerland).
The investigated methods consisted of standard compartmental modeling
using the arterial input function and the one-tissue compartment model.
The parameters are as follows: K1 describes the transport of the tracer
across the blood brain barrier and k2 represents the back-diffusion of label
from tissue to the blood system. Carbon is labeled as ‘C.’ Label exchange
between compartments is described by the following differential equation:
dCtiss
dt
¼ K1Cplasma tð Þ - k2CtissðtÞ
The basis of the calculation of the CBF measurement was also the one-
tissue compartment model including a partition coefﬁcient for 15O-H2O.
16
Metabolite analysis in the blood. Samples (approximately 400 μL) were
collected at different time points after tracer injection, with a maximum of
4 to 5 blood samples per animal, to determine the time-course of the
ratio of the 11C activity in plasma to whole blood and for analysis of
authentic tracer and metabolites. These samples were ﬁrst centrifuged
for 3 minutes at 270 g. Proteins were then precipitated with 75 μL acetoni-
trile in 50 μL plasma. After centrifugation for 3 minutes at 270 g, the
composition of the 11C-derived radioactivity in the supernatant (80 μL) was
analyzed by HPLC on a polymeric column (PRP-1, 5-μm, 250× 4.1 mmol/L
intradermally, Hamilton, Franklin, MA, USA) with 3mmol/L phosphoric acid
in water (pH 2.67) as the mobile phase (1mL/minute). The retention times
of 11C-HCO3
− (3.3 minutes) and lactic acid (5.1 minutes) were determined
by using aqueous solution of NaHCO3 and DL-lactic acid as reference
compounds, detected by ultraviolet absorption at 220 nm. The amount of
authentic tracer was expressed as a fraction of total plasma counts.
Metabolite analysis in brain. At the end of the experiment, the rats were
perfused with PBS, brains were removed and prepared for measurements
with the HPLC system. Each brain was ﬁrst homogenized before
adding acetonitrile (150%, i.e., 1.5 × volume/weight of brain sample).
The subsequent procedure was the same as with the blood samples
described above, except that the amount of supernatant injected into the
HPLC system was 200 μL.
Statistical Analysis
All data are presented as mean± s.d. Statistical analyses were performed
using non-parametric tests; one-way analysis of variance (Kruskal–Wallis
followed by Dunn’s multiple comparison test) was used for analysis of
in vitro experiments and the Mann–Whitney test was used for comparison
between two groups in the in vivo experiments and for the behavioral
experiments. Paired t-test was used to compare protein expression.
Po0.05 was considered statistically signiﬁcant.
RESULTS
HCA1 Receptor Expression and a Possible Neuroprotective Role in
Ischemia
Recent studies revealed the presence and mechanism of action of
the HCA1 receptor (formerly known as GPR81) in the CNS.8–10
Because L-lactate acts as an endogenous ligand for this receptor, it
was of interest to describe the cellular expression of this receptor
in several brain regions affected by ischemic damage in the
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mouse tMCAO model. We conﬁrmed a strong neuronal expression
of the HCA1 receptor in the hippocampus (CA1 and dentate
gyrus), the cortex, and the striatum as revealed by double labeling
immunoﬂuorescence for the HCA1 receptor and the neuronal
markers NeuN or MAP2 (Figure 1: NeuN (green), MAP2 (green),
HCA1 (red), 4,6 diamidino-2-phenylindole (blue)). The next step
was to evaluate whether such HCA1 receptor expression was
altered at different time points after 30minutes tMCAO. For this
purpose, the level of HCA1 receptor expression was evaluated on
Western blots in protein extracts from hippocampus, cerebral
cortex and striatum at 1, 3, 8, 24, and 48 hours after 30 minutes
of tMCAO. Results at 1, 3, and 8 hours did not reveal signiﬁcant
differences between the three brain structures investigated (see
Supplementary Table 1). However, a signiﬁcant increase in HCA1
receptor expression was seen in the ischemic cortex after 24 hours
(1.2 ± 0.2, Po0.05 vs. contralateral cortex; Figure 2A). Even though
there is neuronal loss in the lesion core (ischemic striatum), we did
not observe a signiﬁcant decrease in HCA1 receptor expression in
this structure (0.8 ± 0.3, n.s. vs. contralateral cortex) which may
reﬂect a compensatory increase in HCA1 receptor expression in
remaining neurons (Figure 2A). At 48 hours after ischemia, no
difference could be observed between ischemic and contralateral
tissues (see Supplementary Table 1). On the basis of this result
and the possibility that lactate regulates HCA1 receptor expres-
sion, we injected L-lactate intravenously at the beginning of the
reperfusion period and monitored any changes in HCA1 receptor
expression at 24 hours after the ischemic episode. We found
an increase in HCA1 receptor expression in both the ischemic
cortex (1.57 ± 0.34, Po0.04 vs. contralateral cortex) and ischemic
striatum (1.7 ± 0.4, Po0.05 vs. contralateral striatum) while
no signiﬁcant difference was observed for the hippocampus
(Figure 2B). These observations suggest that the expression of the
HCA1 receptor may be modulated by ischemia and potentially by
lactate injected at reperfusion.
We went on to further investigate the role of HCA1 receptors
under ischemic conditions in an in vitro model. For this purpose,
we used rat organotypic hippocampal slices exposed to an OGD
protocol. We observed a signiﬁcant increase in HCA1 receptor
expression 48 hours after OGD (1.45 ± 0.16, Po0.01 vs. control
slices; Figure 2C). To determine whether the enhanced HCA1
receptor expression could have a role in the neuroprotective
effect of L-lactate in this model, organotypic hippocampal slices
were exposed to the HCA1 receptor agonist 3,5-dihydroxybenzoic
acid after OGD. Results show that 3,5-dihydroxybenzoic acid
produced signiﬁcant protection as it reduced neuronal cell death
in the CA1 region of the hippocampus 48 hours after insult from
13.5 ± 7.2% to 7.4 ± 5.2% (Po0.05; Figure 2D).
D-Lactate Neuroprotection in Ischemia Models
The D enantiomer of lactate has been described to act at least as a
partial agonist of the HCA1 receptor.9,18 For this reason, we tested
the neuroprotective effect of D-lactate both in vitro and in vivo.
The administration of 4 mmol/L D-lactate to rat organotypic
hippocampal slices directly after OGD also resulted in signiﬁcantly
reduced neuronal cell death in the CA1 region of the hippo-
campus 48 hours after OGD, from 29.2 ± 14.3% to 11.3 ± 7.3%
(Po0.05; Figure 3A). It is noteworthy that the neuroprotective
effect approaches that previously reported for L-lactate in this
model.11 We then tested D-lactate in vivo by intravenous adminis-
tration of 1 μmol/g D-lactate after 45 minutes tMCAO. Mice with
satisfactory ischemia (rCBFo20% of baseline) and reperfusion
(rCBF above 50% of baseline) received a single intravenous
administration of D-lactate or vehicle, 10 to 15 minutes after the
silicon-coated monoﬁlament was removed allowing reperfusion. A
total of nine mice were not included in the study as they did not
fulﬁll the rCBF inclusion criteria. Single administration of D-lactate
signiﬁcantly decreased the infarct volume from 81.8 ± 40.1 mm3
(control group) to 45.5 ± 32mm3 (D-lactate group) measured 48
hours after ischemia (Po0.05; Figure 3B). Again, the magnitude
of neuroprotection was comparable with that reported previously
for L-lactate in vivo.12 Behavioral performances on motor task
assessment showed a clearly milder neurological deﬁcit at 48
hours (Po0.05) in the D-Lactate group, from a median of 2.5, with
scores ranging from 1 to 5 (control group), to a median of 1, with
scores ranging from 0 to 1 (D-lactate group, Po0.05, Figure 3C).
One mouse from the control group and two mice from the





1A 1B 1C 1D 1E 1F
2A 2B 2C 2D 2E 2F
3A 3B 3C 3D 3E 3F
4A 4B 4C 4D 4E 4F
NeuN+DAPI HCA1+DAPI NeuN+HCA1+DAPI MAP2+DAPI HCA1+DAPI MAP2+HCA1+DAPI
Figure 1. Confocal visualization of HCA1 receptor expression. Using two different antibodies against neuronal cells, we conﬁrmed with
immunohistochemistry the localization of the HCA1 receptor is in neurons. The brain structures analyzed were hippocampus (CA1 (1a–1f) and
Dentate Gyrus (DG) (2a–2f) regions) primary cortex (3a–3f ) and Striatum (4a–4f). Color code: NeuN (green, a and c), MAP2 (green, d and f),
HCA1 (red, b and c and e and f), 4,6 diamidino-2-phenylindole (blue). Magniﬁcation: 40 μm.
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mice per group were killed within the ﬁrst 6 hours after surgery
because of the presence of repeated seizures as required by the
veterinary authority.
Cerebral D-Lactate Metabolism
Different in vivo and in vitro studies have suggested that D-lactate
is not metabolized in cerebral tissue6,19,20 based on the apparent
lack of expression of the speciﬁc enzyme D-lactate dehydrogenase
in mammals. To clarify this issue in the rodent brain, we set up a
series of experiments using radiolabeled D-lactate to trace its
metabolism and kinetics (Figure 4A). To evaluate the brain uptake
of D-lactate, we determined the ﬁrst pass extraction fraction,
which was 16%. The tissue kinetics of 1-11C-D-lactate displayed an
increase of more than 5minutes and slow washout thereafter on
tracer injection (Figure 4B). The average respective ﬁrst-order
kinetic rate constants obtained by kinetic modeling were
0.059 ± 0.01 mL/minute/mL tissue (K1) and 0.063 ± 0.01 per minute
(k2). Average lactate levels in the blood were 2.2 ± 0.93mmol/L.
11C-CO2 turned out to be the only metabolite in blood and
brain. The time course of the fraction of authentic tracer in arterial
plasma is shown in Figure 4C. The pooled fraction data of all
animals were approximated by a ﬁt of a quadratic polynomial. This
function was subsequently used to convert the total plasma
activity to the time-course of authentic 11C-lactate ( = input curve).
At 40 minutes, the fraction of true tracer in plasma dropped to
approximately 30%. Measurements in brain tissue at the end of
the experiment revealed approximately one-third CO2 and two-
thirds lactate (Figure 4D).
Effect of Pyruvate and Acetate in Ischemia Models
Results obtained on D-lactate metabolism suggest that in addition
to a possible activation of the HCA1 receptor, the use of D-lactate
as an energy substrate may also contribute to its beneﬁcial effect
in ischemia. Therefore, we explored the speciﬁcity of its metabolic
mode of action by testing the neuroprotective effect of two other
monocarboxylates. Pyruvate is the immediate downstream
product of either L- or D-lactate and is the main substrate
entering the Krebs cycle to provide energy. Other groups have
previously described the neuroprotective effect of pyruvate in
different models of cerebral ischemia.2,21 In agreement with these
observations, administration of 10 mmol/L pyruvate directly after
OGD signiﬁcantly decreased cell death in the hippocampal CA1
region at 48 hours from 25.4 ± 14.5% to 13.9 ± 10.3% (Po0.05;
Figures 5A and 5B). In contrast, we did not observe a signiﬁcant
beneﬁt in vivo after tMCAO. In our hands, pyruvate administration
at reperfusion after 30minutes tMCAO induced only a slight
reduction in lesion size (P= 0.4), from 91.9 ± 53.6 mm3 (control
group, n= 7) to 64.6 ± 53.4 mm3 (pyruvate, n= 5) 48 hours after
ischemia. A total of four mice were not included because they did
not fulﬁll rCBF inclusion criteria. There was no mortality in this
experiment. Because of the inherent variability of the model, our
experiment was, however, not powered to detect a signiﬁcant
neuroprotective effect (the sample size calculation using an alpha
error of 5% and a beta error of 50% resulted in a sample size of 21
per group, www.dssresearch.com).
As both L- and D-lactate could be taken up and metabolized in
principle by either neurons or astrocytes, we wanted to determine
24h after tMCAO 24h after tMCAO+ L-lactate 
Figure 2. The HCA1 receptor expression is promoted by ischemia and has a role in the neuroprotective effect. (A) Western blot analysis
showed an increase in the HCA1 receptor expression at 24 hours after transient middle cerebral artery occlusion (tMCAO) in the region
surrounding the lesion site (primary motor and somatosensory cortex), in comparison with the contralateral hemisphere. (B) Intravenous
L-lactate injection prompted an increase also in the lesion site (striatum) at the same time point (*Po0.05; paired t-test ischemic vs.
contralateral hemisphere). (C) Western blot analysis showed an increase in the HCA1 receptor expression at 48 hours after oxygen and glucose
deprivation (OGD) (**Po0.01 paired t-test). (D) Administration of 4mmol/L 3,5-dihydroxybenzoic acid (3,5-DHBA), an HCA1 receptor agonist,
attenuated cell death when administered directly to the medium after OGD (*Po0.05, ***Po0.001 one-way analysis of variance (ANOVA)
Kruskal–Wallis test followed by Dunn’s multiple comparison test).
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whether the beneﬁcial metabolic effect of lactate in vitro could be
exerted via its use by astrocytes. For this purpose, we made use of
acetate which is known to be speciﬁcally taken up and used as
energy substrate by astrocytes.22 However, the addition of
different concentrations of acetate (0.13, 0.2, 4, and 8mmol/L)
to organotypic hippocampal slices 1 hour after OGD did not
provide signiﬁcant neuroprotection (Figures 5A and 5C).
DISCUSSION
After being considered for decades as a waste-product of
metabolism, lactate has been shown to be able to support
synaptic activity1,23 and is nowadays recognized as a prominent
energy substrate in the CNS.24 Lactate is produced under physio-
logic conditions,25,26 and it is suggested to have an important
role in the metabolic support of long axons6,27 as well as in long-
term memory formation.28 Lack of adequate lactate supply
has also been implicated in some neurodegenerative diseases
such as amyotrophic lateral sclerosis.29 Moreover, exogenous
lactate supplementation seems beneﬁcial after traumatic brain
injury.30–32 In ischemic conditions, our group and others have
shown neuroprotection after L-lactate administration at reper-
fusion after tMCAO.11,12,33 Similarly, brain lactate was found to be
essential to improve post-ischemic outcome after cardiac arrest.34
Lactate can be transported from one cell type to another by MCTs
that are selectively expressed in different cell types and which can
transport monocarboxylates with different afﬁnities.35 More
recently, lactate has been described to act as a signaling molecule
in the CNS, either through the HCA1 receptor8,9 or through an
unknown receptor yet to be speciﬁed.36
Our initial characterization of the distribution of the HCA1
receptor in three brain regions affected after tMCAO conﬁrmed a
prominent neuronal expression in the CNS.8,9 Interestingly, our
data also suggested that the cerebral expression of HCA1 can be
modulated under certain conditions. Lactate itself seems to be a
signal for the induction of its own receptor. However, whether
lactate accumulation after ischemia is responsible for the
enhancement of the HCA1 receptor observed after 24 hours of
reperfusion remains to be directly shown. Nonetheless, our results
provide the ﬁrst evidence that activation of HCA1 receptors alone
is sufﬁcient to provide neuroprotection, at least in an in vitro
ischemic model. Our demonstration that neuroprotection was also
achieved with D-Lactate conﬁrms this observation in that D-lactate
was shown to exhibit at least partial agonist activity on HCA1/
GPR81 receptor18,37 and that D-lactate was considered as a non-
metabolizable lactate enantiomer and often used as a negative
control to show the necessity of L-lactate use as an alternative
energy substrate. However, unexpectedly, we found that D-lactate
is extracted by the rodent brain and oxidized. In fact, one third
of D-lactate was metabolized to CO2, which is only marginally
less than the previously reported fraction of CO2 produced
from L-lactate (42 ± 8% CO2 after 40minutes
1). This observation
suggests that the rodent brain may possess a D-lactate dehydro-
genase activity. In accordance, the isolation of human and mouse
transcripts encoding a homolog of the yeast D-lactate dehydro-
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Figure 3. Neuroprotection by D-lactate. (A) In vitro, administration of 4mmol/L D-lactate induced a signiﬁcant reduction in cell death, assessed
by propidium iodide (PI) staining, 48 hours after treatment (*Po0.05, one-way analysis of variance (ANOVA) Kruskal–Wallis followed by Dunn’s
multiple comparison test). In vivo, intravenous injection of 1 μmol/g D-lactate after 45minutes transient middle cerebral artery occlusion
(tMCAO) decreased total infarct volumes measured 48 hours after ischemia (B) and improved the neurologic outcome (C), neurologic deﬁcit
scores from 0, no deﬁcit—white, to 5 worst outcome—black; *Po0.05 Mann–Whitney test, two-tailed P-value.
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tissues, including the brain.38 However, it remains to be deter-
mined whether the presence of a cerebral D-Lactate dehydro-
genase enzyme is sufﬁcient to explain our results or whether the
activity is performed by another a priori unrelated enzyme.
In the CNS, pyruvate is transported mainly by MCT1 and MCT2
in the direction of the concentration gradient, and these MCTs are
located in astrocytes and neurons, respectively.4,39 Possible
explanations for the neuroprotection against ischemic damage
induced by either L- or D-lactate are the fact that lactate is
converted to pyruvate by the mitochondrial lactate dehydrogen-
ase to fuel the Krebs cycle and therefore used as energetic
substrate and that this conversion produces reduced nicotinamide
adenine dinucleotide that will in turn act as a reactive oxygen
species scavenger.40 Evidence pointing towards this metabolic
explanation is the protection exerted by the administration of
10mmol/L pyruvate in vitro. Protection is not seen in vivo though.
However, in support of a metabolism-mediated neuroprotective
effect, others2,21 have shown protection in vivo using an extended
intravenous mode of administration of pyruvate.21 This difference
in the mode of administration may explain the different in vivo
results, although we cannot exclude that lactate may prove to be a
more efﬁcient neuroprotective agent, notably in vivo, in particular
because of the ability of both L- and D-lactate to activate the
HCA1 receptor.
It has been shown that acetate is preferentially transported
by MCT1 and metabolized in astrocytes.17,22 During ischemia, it
was observed that 14C-acetate uptake is decreased as early as
3 minutes after the onset of ischemia. The degree of reduction in
14C-acetate uptake correlates with the severity of ischemia which,
according to Hosoi et al,41 relates to the depression of glial
metabolism. Even though the reduction in 14C-acetate uptake was
reversible and reached full recovery 3 hours after 30 minutes
MCAO, Hosoi et al did not evaluate the functional outcome of
acetate administration. We showed here that the administration of
acetate did not exert protection against neuronal death in
hippocampal slices subjected to oxygen and glucose deprivation.
Even though there is an increased energy demand in neurons and
astrocytes subjected to ischemic insult, this result suggests that
energy supply to astrocytes is not enough to exert neuroprotec-
tion. It should be noted that using an in vitro assay of ligand-
induced 35S-GTPγS binding with membranes from CHO cells
expressing human HCA1 receptor, Cai et al18 described that
neither sodium pyruvate nor sodium acetate showed binding
activity. As neither acetate nor pyruvate binds to the HCA-1
receptor, the results shown here cannot be related to HCA1
signaling pointing to the use of pyruvate and acetate as metabolic
substrates.
Some limitations to consider in the present study are that (1)
our in vivo stroke model involves a transient occlusion with
removal of the silicon ﬁlament, therefore our results are limited to
be translated to patients with either a spontaneous reperfusion
or successful intravenous thrombolysis or intrarterial recanalisa-
tion. Evaluating the effect of lactate administration in permanent
ischemia is an important step before aiming for translation in
clinical practice. (2) Ischemia is induced under isoﬂurane

















Figure 4. D-lactate metabolism. (A) Schematic of biochemical pathways involved in the degradation of lactate and the proposed
interpretation of the rate constants K1 and k2 which are mathematically deﬁned by the one-tissue compartment model used for 1-
11C-D-
lactate data analysis. (B) Measured radioactivity concentration in the brain (open circles), model ﬁt (black line), and arterial input curve (gray
line). The inset displays the residuals of the ﬁtting to the one-tissue compartment model. Equal distribution around the neutral line supports
the adequacy of the applied model. (C) Fraction of native radiolabeled lactate more than 40minutes after intravenous injection of 1-11C-D-
lactate in the blood. The ﬁlled circles represent data points from individual measurements and the solid line is the corresponding ﬁt.
(D) Percentage of identiﬁed metabolites in brain tissue after 40minutes.
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neuroprotective by itself. Therefore, we may not be observing the
neurologic damage to its fullness. In organotypic hippocampal
slice cultures the tissue architecture is only partially preserved and
while some neuronal connections are maintained many are
interrupted. Furthermore, there is no blood circulation. Despite
these limitations, both models complement each other and
strengthen our observations. (3) It should be considered as well
that lactate was shown to increase regional CBF in physiologically
activated but not resting human brain.42 Although we cannot rule
out a contribution from CBF changes, the effect observed in the
in vitro model, independently from blood ﬂow, shows that lactate
exerts a neuroprotective effect independently from possible
effects on cerebral blood ﬂow.
Taken together, these data point to the possibility that lactate,
independently of the enantiomer type, may confer neuroprotec-
tion after ischemia by two distinct mechanisms: One, through the
classic metabolic pathway providing an alternative energy supply
to deprived neurons and the other through a receptor-mediated
signal transduction mechanism in neurons. In both cases, the
exact targets within the cell still need to be identiﬁed.
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